Skip to main content
PLOS One logoLink to PLOS One
. 2026 Jul 22;21(7):e0353985. doi: 10.1371/journal.pone.0353985

In silico identification and biophysical characterization of candidate antimicrobial peptides from the Indian marine microbiome targeting multidrug-resistant ESKAPE pathogens

Sreelakshmi K V 1, Nasri Thaha 1, Budheswar Dehury 1,*
Editor: Salman Sadullah Usmani2
PMCID: PMC13390849  PMID: 42485280

Abstract

The global health crisis of antimicrobial resistance necessitates the discovery of new antibacterial agents. Underexplored marine microbiomes, particularly from the biodiverse Indian coast, represent a rich potential source of antimicrobial peptides (AMPs). Targeting the urgent threat of multidrug-resistant ESKAPE pathogens, the present study aimed to computationally identify novel, membrane-active AMPs from these unique metagenomic datasets, with a focus on inhibiting Gram-negative bacteria. In this study, we computationally mined Indian marine high-resolution shotgun metagenomic datasets through quality filtering, de novo assembly, and small open reading frame prediction. An ensemble of six machine learning-based AMP prediction tools identified over 51,000 high-confidence candidate AMPs. Subsequent filtering based on physicochemical properties and AlphaFold3-predicted structures prioritized ten peptides with favourable membrane-active characteristics. Two lead candidates, c_AMP_1 and c_AMP_2, were subjected to all-atom molecular dynamics simulations within Gram-negative membrane mimetic models of Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Our simulations indicated distinct membrane interaction modes: c_AMP_1 adopted a stable, surface-associated α-helical orientation, while c_AMP_2 displayed a more flexible, membrane-inserting orientation in the simulations. Analysis of the MD simulations revealed distinct predicted peptide-membrane interaction profiles, characterized by specific hydrogen bonding patterns, peptide tilt angles, and membrane thinning, which collectively suggest differing biophysical interaction modes. Taken together, our work suggests the Indian marine microbiome as a promising reservoir for novel AMP candidates and suggests that an integrated computational pipeline – combining machine learning, structural biology, and biophysical simulation – may help prioritize candidate peptides for future experimental validation against critical pathogens.

1. Introduction

The rise of antimicrobial resistance (AMR) has become a critical global health concern in the modern era. The proliferation of resistant bacterial strains increasingly undermines the efficacy of conventional antibiotics, which threatens to reverse decades of medical progress in treating infectious diseases [1]. Recent comprehensive analyses estimated that bacterial AMR was associated with approximately 4.71 million deaths worldwide in 2021, with 1.14 million deaths directly attributable to resistant infections, underscoring the gravity of this crisis [2]. The primary drivers of AMR include the overuse and misuse of antibiotics in human and veterinary medicine, inadequate infection prevention and control measures, and the environmental dissemination of resistance genes facilitated by anthropogenic activities [3]. The uneven distribution of the AMR burden complicates this issue significantly, especially for low- and middle-income countries (LMICs). In these regions, the lack of access to diagnostic services and second-line therapies exacerbates health problems, resulting in increased morbidity and mortality [4]. India, in particular, bears one of the highest burdens of drug-resistant infections globally and reported nearly 300,000 deaths attributable to AMR in 2019 alone [5]. Due to the growing challenge of AMR, organizations such as the World Health Organization (WHO) have emphasized the need for comprehensive global action, including the development of new antimicrobial therapies, enhanced surveillance, and coordinated international efforts to limit its progression.

Within the spectrum of AMR-related challenges, ESKAPE pathogens, comprising Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, have been highlighted because of their prominent role in nosocomial infections and notorious ability to “escape” the lethal action of antibiotics. These pathogens account for a significant fraction of hospital-acquired infections worldwide and exhibit multidrug resistance patterns that severely limit therapeutic options [6]. Studies conducted in diverse healthcare settings, including tertiary hospitals across South Asia and the Middle East, have revealed an alarmingly high prevalence of multidrug-resistant (MDR) strains within the ESKAPE group, with notable resistance to critical antibiotics such as carbapenems and oxacillin [7]. In India, the increasing threat posed by ESKAPE pathogens is especially concerning. A study that examined 20,177 isolates revealed that Acinetobacter baumannii was the most prevalent, accounting for 35.9% of the total. It was followed by Pseudomonas aeruginosa at 25.3% and Klebsiella pneumoniae at 19.5% [8]. The clinical and economic burden of infections caused by these pathogens is substantial, necessitating rigorous infection control measures, antimicrobial stewardship programs, and accelerated development of novel therapeutic agents, as articulated in recent WHO priority pathogen lists. The persistence and adaptability of ESKAPE bacteria highlight an urgent need for innovative strategies that transcend traditional antibiotic development paradigms.

Antimicrobial peptides (AMPs) have emerged as promising candidates in the battle against multidrug-resistant pathogens, including the ESKAPE group. These short, naturally occurring peptides demonstrate strong and broad-spectrum antimicrobial activity, with the ability to target a wide range of microorganisms, including bacteria, viruses, fungi, and even cancerous cells [9,10]. Their primary mode of action involves interacting with microbial membranes through electrostatic attractions, followed by insertion into the membrane due to their amphipathic nature, ultimately leading to membrane disruption and cell lysis. In addition to their membrane-targeting effects, some AMPs can penetrate microbial cells and interfere with essential intracellular processes such as nucleic acid synthesis and protein folding [11]. Unlike conventional antibiotics, which typically target singular bacterial processes, AMPs engage multiple pathways concurrently, rendering the evolution of resistance more difficult for pathogens. Their rapid bactericidal action coupled with their immunomodulatory properties, such as the recruitment of immune cells and the regulation of inflammatory responses, confers additional therapeutic advantages [12]. Furthermore, AMPs display preferential selectivity towards bacterial membranes over mammalian cells due to differences in membrane composition, which translates to relatively low cytotoxicity [13]. Recent advancements have also demonstrated that AMPs can synergize with existing antibiotics, restoring susceptibility in resistant strains, as exemplified by LL-37’s ability to resensitize colistin-resistant bacteria [14]. Collectively, these attributes position AMPs as promising candidates for next-generation antimicrobials, with potential applications spanning systemic infections, wound healing, and biofilm disruption.

Marine ecosystems have garnered significant attention as reservoirs of untapped AMP diversity, driven by their unique environmental conditions that foster the evolution of microorganisms with novel bioactive compounds [15,16]. The marine biome encompasses a vast array of habitats characterized by high salinity, variable pressure, and nutrient limitations, selecting for microbes equipped with specialized metabolic pathways and distinctive antimicrobial properties [17,18]. Recent large-scale metagenomic studies have expanded our understanding of global marine microbial diversity, revealing an unprecedented number of biosynthetic gene clusters (BGCs) responsible for the synthesis of novel bioactive molecules, including AMPs, many of which show low sequence similarity to previously identified peptides, suggesting the existence of entirely new antimicrobial scaffolds [19,20]. This emphasizes the vast potential of marine environments as a valuable source for identifying novel and potent antimicrobial peptides.

The Indian marine microbiome harbors exceptional taxonomic and functional diversity yet remains significantly underexplored as a source for AMP discovery and bioprospecting. India’s extensive coastline, spanning over 7,500 kilometres and encompassing diverse ecosystems such as mangroves, coral reefs, and deep-sea sediments, offers a unique milieu for microbial innovation [21,22]. Metagenomic surveys across various Indian aquatic systems have revealed high bacterial diversity, including genera known for antibiotic production and resistance gene reservoirs [18,23]. However, the majority of these ecosystems remain inadequately characterized in terms of their AMP repertoire, offering immense scope for novel peptide discovery.

The integration of artificial intelligence (AI) and machine learning (ML) techniques into AMP discovery pipelines has significantly enhanced the efficiency of screening, prediction, and optimization processes across large-scale metagenomic datasets [24,25]. Traditional wet-lab approaches, while essential, are constrained by time, cost, and scale, limiting the pace of novel AMP identification. By leveraging advanced pattern recognition, sequence-based feature extraction, and predictive modeling, AI/ML approaches enable the identification of antimicrobial potential, toxicity profiles, and possible mechanisms of action directly from primary peptide sequences, substantially accelerating early-stage discovery and development efforts [26,27]. Recent advances in deep learning, using architectures such as convolutional and recurrent neural networks, graph-based models, and protein language models adapted from natural language processing, have significantly improved the accuracy of AMP classification and functional annotation. These models can capture subtle structural and physicochemical characteristics, enhancing the prediction of peptide efficacy [28,29]. The integration of high-throughput metagenomic sequencing with advanced machine learning algorithms has further accelerated the pace of AMP discovery. A landmark study by Santos-Júnior et al. exemplified this synergy, identifying nearly one million AMP candidates from global metagenomes, including those from marine ecosystems, over 90% of which were novel and previously uncharacterized [30]. The integration of AI/ML with well-curated AMP databases enables a data-driven and scalable framework for mining Indian marine metagenomes, making the discovery process more systematic, efficient, and rapid.

The present study aims to computationally prioritize and biophysically characterize candidate AMPs from Indian marine metagenomic datasets with predicted activity against ESKAPE pathogens. By integrating advanced machine learning-based AMP prediction tools, structural modelling, and all-atom molecular dynamics simulations, this study identifies and characterizes candidate membrane-active peptides from metagenomic data. Crucially, all-atom molecular dynamics simulations were performed in biologically relevant membrane models – an asymmetric outer membrane model for Acinetobacter baumannii and symmetric inner membrane models for Klebsiella pneumoniae and Pseudomonas aeruginosa – enabling detailed insights into predicted peptide-membrane interaction modes, orientation states, and conformational dynamics. This integrated computational framework aids in the discovery and prioritization of candidate AMPs and provides biophysical characterization of their predicted membrane interaction profiles, providing a computational basis for future experimental validation. Our findings contribute to a deeper understanding of how marine-derived AMPs may overcome bacterial resistance mechanisms through membrane targeting. This study not only highlights the untapped potential of India’s marine microbial diversity in drug discovery but also supports broader national and global initiatives such as the blue economy, “Make in India,” and the One Health framework. Ultimately, sustainable development goals (SDGs) 3 and 14 are advanced by the promotion of novel antimicrobial strategies and sustainable marine resource utilization.

2. Materials and methods

2.1. Dataset selection and acquisition

Five publicly available whole-genome shotgun (WGS) metagenomic datasets were retrieved from the National Center for Biotechnology Information (NCBI) BioProjects and the European Nucleotide Archive (ENA). Dataset selection was performed using targeted search queries containing marine-related keywords in conjunction with the term “India,” with additional filtering for experiments explicitly designated as “METAGENOMIC” in their library source metadata. Stringent inclusion criteria were applied to ensure dataset relevance and quality: (i) data type specified as WGS metagenomic sequences, (ii) submission date after January 1, 2020, (iii) sequencing platform restricted to Illumina to maintain consistency in read quality and format, and (iv) minimum project size of 5 samples to ensure robust representation.

2.2. Sequence pre-processing, assembly, and gene prediction

Raw sequencing reads in FASTQ format were downloaded for all selected metagenomic samples. The initial quality assessment of sequencing data was performed using FastQC to examine base quality, adapter contamination, and other key quality parameters. The reads were then processed using Trimmomatic [31], which removes low-quality bases and adapter sequences based on stringent filtering parameters (quality score threshold: Q ≥ 25; minimum read length: 60 bp). After filtering, FastQC was rerun to confirm improvements in quality. High-quality, adapter-free reads were subsequently assembled de novo into contigs using MEGAHIT (v1.1) [32], which was optimized for large and complex metagenomic datasets. Assembly was performed using the parameters --min-count 2 --k-min 33 --k-max 63 --k-step 10 for each sample, generating contigs that served as the basis for downstream gene prediction and peptide mining. Small open reading frames (smORFs) ranging from 33–303 base pairs were predicted from the assembled contigs using MetaProdigal [33], enabling the identification of potential coding sequences from metagenomic assemblies. To minimize redundancy yet preserve structural and functional diversity, the protein sequences translated from these smORFs were clustered using CD-HIT [34]. Clustering was performed with the following parameters: -n 2 -p 1 -c 0.5 -d 200 -M 50000 -l 5 -s 0.95 -aL 0.95 -g 1, requiring family members to share atleast 50% sequence homology [16]. Additionally, shorter sequences were required to be at least 95% the length of the cluster representative, and alignments were required to cover at least 95% of the longer sequence. The resulting non-redundant set of smORF-encoded proteins was retained for subsequent AMP prediction.

2.3. ML-based AMP prediction and novelty assessment

Six distinct machine learning-based tools were used to assess the antimicrobial potential of the non-redundant peptide dataset. These included AMPlify [35], ampir [36], AMPScanner v2 [29], AI4AMP [37], amPEPpy [38], and APIN [39]. Each tool applies distinct algorithmic strategies and sequence features for AMP classification, including physicochemical descriptors, evolutionary information, and deep learning embeddings. Only peptides that were consistently predicted as AMPs by all six tools were retained for further evaluation, suggesting a high-confidence set of candidate antimicrobial peptides. The confidence of this consensus-based approach is supported by the independent benchmarking of each constituent tool against curated AMP and non-AMP reference datasets in their respective original publications, with reported accuracies ranging from 85% to 97%. However, no additional independent benchmarking was performed within this study, which represents a limitation of the current pipeline. To assess the novelty of the predicted AMPs, BLASTp searches were conducted against CAMP R4 and other curated AMP databases using an E-value cut-off of 10 ⁻ ⁵ and a maximum sequence identity threshold of 40%. Peptides showing low similarity to known AMPs were retained as putative novel candidates.

2.4. Cell-penetrating peptide (CPP) screening and physicochemical profiling

High-confidence AMPs were further evaluated for their cell-penetrating potential using two complementary machine learning-based CPP prediction tools: pLM4CPPs [40] and CellPPD-Mod [41]. Peptides shorter than 50 amino acids and containing both arginine (R) and tryptophan (W) residues were prioritized due to their established roles in mediating membrane interaction and cellular uptake. For CellPPD-Mod, peptides with a prediction score greater than 0 were classified as CPPs (default threshold). For pLM4CPPs, the default classification threshold was applied. Additionally, similarity searches were performed against CPPsite 3.0 [42], an updated curated database of 4143 experimentally validated CPPs, using the Smith-Waterman algorithm, to assess the sequence similarity of shortlisted candidates to known CPPs. The top 10 candidates were subjected to physicochemical property analysis via the DBAASP server [43], with parameters calculated on the Moon-Fleming hydrophobicity scale. Parameters such as the net charge, hydrophobicity, and isoelectric point were computed to assess their suitability for further evaluation. In silico toxicity and haemolytic activity of all ten shortlisted peptides were additionally assessed using ToxinPred 3.0 [44] and HemoPI 2.0 [45] respectively, to obtain a preliminary predicted safety profile. On the basis of these properties, only two peptides with optimal antimicrobial potential and desirable biochemical profiles were advanced to structural modelling and all-atom molecular dynamics simulations. The selection was guided by a multi-criteria evaluation framework that considered the highest consensus scores across all six machine learning prediction tools, contrasting yet complementary physicochemical profiles, and structurally distinct AlphaFold3-predicted conformations enabling a meaningful comparative biophysical analysis. The considerable computational demands of 300 ns all-atom simulations across three bacterial membrane systems further necessitated a focused selection of the most structurally divergent candidates. Three-dimensional structural models of the selected peptides were generated using AlphaFold3 [46], enabling accurate structural representation for interaction studies.

2.5. System preparation for molecular dynamics simulations

Biologically relevant membrane models have been developed to simulate the interaction between antimicrobial peptides and bacterial membranes. For this study, we focused on three clinically significant Gram-negative bacteria: Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Symmetric inner membrane models for K. pneumoniae and P. aeruginosa were constructed based on aggregated lipidomic data, incorporating detailed information on both lipid headgroup and tail compositions to closely mimic native bacterial membranes [47]. In contrast, an asymmetric outer membrane model was specifically designed for A. baumannii, reflecting the distinct lipid distributions in its outer and inner leaflets, as reported in species-specific lipidomic studies [48]. All membrane systems were generated using the CHARMM-GUI Membrane Builder, a widely used tool for creating all-atom lipid bilayer structures. The CHARMM36 force field was utilized to precisely assign lipid topologies and parameterize interatomic interactions with high fidelity [49]. Each membrane bilayer was placed within a tetragonal simulation box of sufficient size to include peptides, water molecules, and ions, thereby maintaining a realistic aqueous environment. It should be noted that the three membrane models employed are not architecturally equivalent. The A. baumannii model incorporates an asymmetric outer membrane containing Lipid A/LPS, reflecting its biologically distinct outer membrane composition, while the K. pneumoniae and P. aeruginosa models represent symmetric inner membrane phospholipid bilayers lacking LPS, based on available validated lipidomic data. This distinction was necessitated by the availability of species-specific validated membrane compositions and reflects the current state of bacterial membrane modeling resources. Accordingly, cross-species comparisons of peptide-membrane interaction metrics should be interpreted with this architectural difference in mind. Initial peptide placement and orientation relative to the membrane were handled using the default parameters of CHARMM-GUI Membrane Builder, which automatically positions the peptide in the aqueous phase above the membrane surface during system assembly. The two selected peptides, c_AMP_1 and c_AMP_2, were each simulated independently in all three bacterial membrane models (A. baumannii, K. pneumoniae, and P. aeruginosa), yielding a total of six independent MD simulation systems (two peptides × three membranes). No additional peptides were carried forward to the MD stage. The detailed lipid compositions used for each membrane system are summarized in Table 1.

Table 1. Lipid composition of bacterial membrane systems used in MD simulations. The table summarizes the distributions of major phospholipid species—phosphatidylethanolamine (PE), phosphatidylglycerol (PG), and cardiolipin (CL)—in the upper and lower leaflets of the simulated membranes for Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Bacterium Leaflet Phosphatidylethanolamine (PE) Phosphatidylglycerol (PG) Cardiolipin (CL) Lipid A/LPS
A. baumannii (OM) Upper (outer) 18% 4% 3% 75% hepta-acyl lipid A
Lower (inner) 72% 16% 12% –
K. pneumoniae Symmetric 80% 15% 5% –
P. aeruginosa Symmetric 65% 23% 12% –

2.6. All-Atom MD simulations

GROMACS version 2023.1 was used to perform all-atom molecular dynamics (MD) simulations using deprotonated lipids and the CHARMM36 force field [50,51]. TIP3P water molecules were introduced into the structure created by CHARMM-GUI to completely submerge the system and replicate an aqueous environment that is biologically relevant. Counter-ions were introduced using a Monte Carlo algorithm to neutralize the system’s net charge, and sodium chloride (NaCl) was included at physiological concentrations to mimic the ionic milieu of bacterial cells [52,53]. Energy minimization was achieved using the steepest descent method, followed by a 1 ns equilibration period in which the temperature was gradually increased from 100 K to 310.15 K. A 300 ns production run was then conducted under constant pressure and temperature (NPT) conditions, maintaining 310.15 K and 1 atm. Each simulation system was run as a single trajectory. While multiple replicates would further strengthen statistical confidence, the computational demands of six independent 300 ns all-atom simulations precluded this in the current study. Long-range electrostatics were handled with the particle-mesh Ewald (PME) method, and a 1 nm cut-off was applied for short-range interactions.

2.7. Post-MD analysis

All molecular dynamics simulation analyses were conducted using GROMACS [50] and VMD [54], with PyMOL employed for structural visualization. Structural stability and flexibility were evaluated through the root mean square deviation (RMSD) and root mean square fluctuation (RMSF), whereas the compactness of each peptide was assessed using the radius of gyration. Solvent accessibility was analysed via solvent-accessible surface area (SASA) calculations. Peptide-membrane interactions were assessed by quantifying hydrogen bonds, defined using a donor-acceptor distance cutoff of ≤3.0 Å and a donor-hydrogen-acceptor angle of ≥150°, consistent with standard GROMACS hydrogen bond criteria and by calculating the membrane tilt angle to evaluate peptide orientation relative to the membrane normal. The membrane thickness and area per lipid were further quantified using FATSLiM [55]. The evolution of secondary structural elements over the simulation trajectory was examined using DSSP, and contact maps were generated using CONAN to identify persistent residue-level interactions within the peptide [56]. Additionally, the C.O.M. of in-contact peptide residues was monitored to track peptide positioning and orientation during membrane binding. Representative system snapshots were extracted every 100 ns to visualize the dynamic conformational changes throughout the 300 ns simulations.

3. Results

3.1. Identification and characterization of candidate AMPs from Indian marine microbiomes

To explore the antimicrobial potential of Indian marine microbiomes, we selected five high-quality metagenomic datasets deposited in the NCBI BioProject, which represent diverse ecological niches such as seawater, sponge, sediment, and coral environments across the Indian coastline. The datasets - PRJNA822508, PRJNA891635, PRJNA900060, PRJNA928230, and PRJNA971765 – comprised a total of 59 metagenomic samples, all sequenced using Illumina platforms after 2020 (Table A in S1 File). Overall, they yielded over 925 million raw sequencing reads. After quality control using Trimmomatic (Q ≥ 25, minimum read length ≥ 60 bp), approximately 85.8% of the reads were retained as high-quality, adapter-free sequences. These trimmed reads were assembled using MEGAHIT with a multi-kmer strategy, generating ~32.6 million contigs across all datasets. From these assemblies, ~ 35.2 million open reading frames (ORFs) were predicted using MetaProdigal, of which ~29.1 million (82.6%) were classified as small ORFs (smORFs) in the range of 33–303 bp (Table B in S1 File).

To remove redundancy and enrich for structurally unique peptides, we applied CD-HIT clustering with stringent identity thresholds (≥50% identity, ≥ 95% coverage). This reduced the dataset to ~24.2 million non-redundant smORFs, representing approximately 83.1% of the original smORF space. These peptides were then screened using six state-of-the-art machine learning-based AMP prediction tools: AMPScanner v2, AMPlify, APIN, ampir, AI4AMP, and amPEPpy. Only sequences that were consistently classified as AMPs by all six tools were retained, resulting in a total of 51,185 c_AMPs, representing ~0.21% of the non-redundant dataset (S2 File).

The c_AMPs were further filtered using a length cut-off of ≤50 amino acids and required the presence of both arginine (R) and tryptophan (W) residues, with potential membrane-penetrating ability. The peptides were subsequently evaluated using pLM4CPPs and CellPPD-Mod to identify potential cell-penetrating candidates. Nine of the ten shortlisted peptides were consistently predicted as CPPs by both tools, supporting their cell-penetrating potential. One peptide, c_AMP_6, yielded conflicting predictions, classified as CPP by pLM4CPPs but as Non-CPP by CellPPD-Mod, and its cell-penetrating ability is noted as requiring experimental confirmation. CPP prediction results are summarized in Table C in S1 File. Similarity searches against CPPsite 3.0 revealed low alignment scores [13–19] across short local windows (3–9 residues) for all ten candidates, and the results are provided in Table D in S1 File. The final set of 10 peptides underwent physicochemical characterization using the DBAASP server, which indicated that they were strongly cationic (net charges between +4 and +11), had high isoelectric points, and displayed moderate to high levels of hydrophobicity and amphipathic properties (Table 2).

Table 2. Sequences and physicochemical features of the top 10 predicted membrane-penetrating antimicrobial peptides (c_AMPs). The physicochemical properties of the antimicrobial peptides, including sequence length, net charge, hydrophobicity etc., were calculated.

ID Sequence Length Normalized Hydrophobic Moment Normalized Hydrophobicity Net Charge Isoelectric Point Penetration Depth Amphiphilicity Index
c_AMP_1 RWVAKRTRKFPRKYTQVAKKKTLLARLILYLIG 33 1.2 0.38 11 12.02 26 1.59
c_AMP_2 GHDEAKAFMTCGLAGKRGGKAPRRWQHLGNMLNRLLSCRS 40 0.57 0.69 6 11.26 21 0.89
c_AMP_3 FWLLGRWLRGLWRKRKAEQAAS 22 0.62 0.62 5 12.13 18 1.84
c_AMP_4 DLGIRTAEKLEKKIRWFIKGRKAVKKLFEKEARHLNCF 38 1.17 0.7 7 10.85 30 1.38
c_AMP_5 RWVSKRIRKFPRKYKHILRKTILYFIGS 28 1.3 0.63 10 12.01 15 1.75
c_AMP_6 GSSFLKGGLCGRKSGGLLQVLQRWIKG 27 0.74 0.03 5 11.49 14 0.94
c_AMP_7 KKAARDHKRWWQVARHTARLIVGSAA 26 1.12 0.74 6 12.14 16 1.49
c_AMP_8 REYGKRLRTGNAPLLLTGGVLALAGLLGGKRGWRRWARLALIVAPLLRRR 50 0.49 0.03 11 12.48 14 1.04
c_AMP_9 LSRPPDVGMRWKWVLAAAAAKAALCGWHTTLLQAKTKAATLV 42 0.13 −0.3 5 11.07 2 1.03
c_AMP_10 PRWMRRFNRGMALLLLLSAWAAAFW 25 0.59 −0.42 4 12.58 12 1.22

In silico safety profiling revealed that all ten shortlisted peptides were predicted as non-toxic by ToxinPred 3.0. HemoPI 2.0 predicted nine out of ten peptides as hemolytic based on binary classification; however, predicted HC50 values ranged from 18.3 to 126.4 μM, indicating variable but moderate predicted hemolytic potency. Notably, c_AMP_2, one of the two lead candidates selected for MD simulations, exhibited a higher HC50 value of 65.6 μM, and c_AMP_7 was classified as non-hemolytic with an HC50 of 126.4 μM, suggesting comparatively lower predicted hemolytic activity among the shortlisted candidates. These in silico predictions provide a preliminary safety assessment and should be confirmed through experimental hemolysis assays. The complete safety prediction results are summarized in Table G in S1 File.

3.2. Structural and functional characterization of selected peptides

Predicted structures of the ten shortlisted cell-penetrating antimicrobial peptides and their corresponding helical wheel diagrams revealed conserved amphipathic features and structural diversity among candidates (Fig. A in S1 File and Fig. B in S1 File). Among these, c_AMP_1 and c_AMP_2 were the only two peptides advanced to all-atom MD simulations, selected based on their contrasting physicochemical profiles, specifically net charge (+11 vs +6), hydrophobic moment, and amphiphilicity index, structurally distinct AlphaFold3-predicted conformations, and highest consensus scores across all six ML prediction tools, enabling a meaningful comparative biophysical analysis. c_AMP_1 demonstrated a high net positive charge of +11, an amphiphilicity index of 1.59, and a membrane penetration depth of 26 Å, suggesting strong electrostatic interactions and a predicted potential for membrane insertion. In comparison, c_AMP_2 exhibited a lower net charge (+6), moderate amphiphilicity (0.89), and a shallower insertion depth of 21 Å, reflecting a more balanced distribution of hydrophobic and polar residues.

AlphaFold3-based structural predictions showed that c_AMP_1 adopts a continuous α-helical conformation (Fig 1A), enriched with basic residues like Arg and Lys. Its helical wheel diagram confirmed a classic amphipathic layout, segregating hydrophobic and polar residues (Fig 1B). In contrast, c_AMP_2 forms a semi-helical structure with flexible termini (Fig 1C), while retaining a clearly amphipathic core region (Fig 1D). These structural features are consistent with typical membrane-active AMPs, predicted to orient favorably in bacterial bilayers. Together, these parameters supported the selection of c_AMP_1 and c_AMP_2 as representative peptides for further structural and dynamic evaluation in lipid bilayer systems.

Fig 1. Predicted structural features of c_AMP_1 and c_AMP_2.

Fig 1

(A) Predicted 3D structure of c_AMP_1 showing a distinct α-helical conformation. (B) A helical wheel representation of c_AMP_1 depicts the arrangement of amino acids, with blue highlighting cationic residues and yellow representing hydrophobic side chains. (C) Predicted 3D structure of c_AMP_2 highlighting α-helical regions. (D) The helical wheel diagram of c_AMP_2 visualizes residue distribution, where blue corresponds to positively charged amino acids and yellow indicates hydrophobic regions.

3.3. Structural stability and conformational flexibility

The structural stability and flexibility of c_AMP_1 and c_AMP_2 were evaluated in the outer membrane of A. baumannii and the symmetric membranes of K. pneumoniae and P. aeruginosa over 300 ns of all-atom MD simulations. Metrics including RMSD, RMSF, SASA, and Rg were used to assess conformational dynamics and membrane engagement. In the A. baumannii outer membrane, c_AMP_1 achieved equilibrium within the first 40−50 ns, maintaining stable RMSD values ranging between 1.25 and 1.35 Å (Fig 2A). A minor transient increase (~1.5 Å) occurred near 120 ns but quickly returned to baseline. The RMSF profile showed minimal fluctuations within the central helical region (residues 12−28), while terminal residues exhibited higher mobility, with a peak of 2.3 Å at the C-terminus (Fig 2B). c_AMP_2 exhibited more flexibility, stabilizing around 2.3–2.6 Å after 80 ns, with RMSF values reaching ~3.0 Å at the C-terminal end. SASA analysis revealed that c_AMP_1 was more solvent-exposed (~49.6 nm²), suggesting surface association, while c_AMP_2 maintained a lower SASA (~31.4 nm²), consistent with deeper membrane embedding (Fig 2C). Rg values remained stable, with c_AMP_1 averaging ~1.36 nm and c_AMP_2 showing tighter compaction at ~1.14 nm (Fig 2D).

Fig 2. Structural dynamics of c_AMP_1 and c_AMP_2 in the A. baumannii membrane.

Fig 2

(A) RMSD trajectories showing backbone stability over time. (B) RMSF plots reflecting residue-level flexibility. (C) SASA data illustrating how much of the peptide remained in contact with the surrounding solvent. (D) Rg profiles highlight the structural compactness of the peptides during simulations.

In the K. pneumoniae membrane, both peptides demonstrated comparable structural trends. c_AMP_1 stabilized with RMSD values around 1.3 Å and maintained these values throughout the simulation (Fig 3A). RMSF again revealed rigid core residues and flexible termini, peaking at 2.1 Å (Fig 3B). c_AMP_2 showed consistent dynamics, with RMSD ranging between 2.2 and 2.5 Å and higher C-terminal fluctuations (~3.1 Å), indicating continued flexibility in this membrane. SASA values followed the same pattern, with c_AMP_1 exposed (~48.7 nm²) and c_AMP_2 more buried (~30.1 nm²) (Fig 3C). Rg profiles remained stable for both peptides, averaging 1.35 nm for c_AMP_1 and 1.13 nm for c_AMP_2 (Fig 3D).

Fig 3. Structural dynamics of c_AMP_1 and c_AMP_2 in the K. pneumoniae membrane.

Fig 3

(A) RMSD trajectories showing backbone stability over time. (B) RMSF plots reflecting residue-level flexibility. (C) SASA data illustrating how much of the peptide remained in contact with the surrounding solvent. (D) Rg profiles highlight the structural compactness of the peptides during simulations.

In the P. aeruginosa membrane, peptide dynamics were consistent with prior systems but slightly more restrained. c_AMP_1 reached RMSD equilibrium early and remained within 1.2–1.3 Å throughout (Fig 4A), with RMSF values under 1.0 Å in the helical core and a peak of 2.4 Å at the N-terminus (Fig 4B). c_AMP_2 displayed marginally reduced RMSD (2.1–2.4 Å) and RMSF fluctuations compared to other membranes, suggesting a slightly more stabilized configuration in this environment. SASA analysis again indicated c_AMP_1 was surface-oriented (~47.2 nm²), while c_AMP_2 was more shielded (~29.0 nm²) (Fig 4C). Rg values for c_AMP_1 ranged between 1.25 and 1.34 nm, while c_AMP_2 maintained its compact structure (~1.08–1.15 nm) (Fig 4D).

Fig 4. Structural dynamics of c_AMP_1 and c_AMP_2 in the P. aeruginosa membrane.

Fig 4

(A) RMSD trajectories showing backbone stability over time. (B) RMSF plots reflecting residue-level flexibility. (C) SASA data illustrating how much of the peptide remained in contact with the surrounding solvent. (D) Rg profiles highlight the structural compactness of the peptides during simulations.

These analyses suggest that both peptides maintain structurally stable and compact conformations across all three bacterial membrane models, with c_AMP_2 exhibiting lower flexibility and solvent exposure compared to c_AMP_1. These predicted properties support their candidacy for further mechanistic evaluation of membrane interaction.

3.4. Peptide insertion kinetics and orientation in bacterial membranes

To evaluate the dynamics of peptide-membrane interactions, molecular dynamics snapshots were extracted at 0, 100, 200, and 300 ns for c_AMP_1 and c_AMP_2 across three bacterial membranes, A. baumannii, K. pneumoniae, and P. aeruginosa (Fig 5 and Fig 6).

Fig 5. Representative MD snapshots showing the progressive membrane interaction of c_AMP_1 in bacterial systems.

Fig 5

Snapshots captured at 0, 100, 200, and 300 ns illustrate the progressive association and partial embedding of c_AMP_1 within the lipid bilayers of (A) A. baumannii, (B) K. pneumoniae, and (C) P. aeruginosa.

Fig 6. Representative MD snapshots illustrating rapid and stable membrane embedding of c_AMP_2 across bacterial systems.

Fig 6

Snapshots at 0, 100, 200, and 300 ns highlight the swift insertion and persistent alignment of c_AMP_2 within the bilayers of (A) A. baumannii, (B) K. pneumoniae, and (C) P. aeruginosa.

In all three bacterial membranes, c_AMP_1 demonstrated a gradual and surface-associated mode of interaction (Fig 5). At 0 ns, the peptide was positioned near the solvent interface. By 100 ns, partial alignment with the membrane surface was observed. At 200 ns, c_AMP_1 established persistent surface contact without deep insertion. By 300 ns, the peptide remained superficially embedded, aligning parallel to the membrane plane, particularly in A. baumannii and K. pneumoniae. In P. aeruginosa, limited penetration into the bilayer was observed, suggesting membrane composition may influence peptide orientation and depth.

c_AMP_2 exhibited markedly different behavior. In all three systems, it approached the membrane early and began embedding by 100 ns (Fig 6). At 200 ns, the helical segment was deeply inserted, and by 300 ns, the peptide adopted a transmembrane orientation in K. pneumoniae and a partially buried tilt in P. aeruginosa. In A. baumannii, it achieved the deepest insertion, where most of the hydrophobic core was fully embedded. This suggests that c_AMP_2 undergoes rapid membrane insertion and stabilizes within the bilayer interior.

Quantitative analyses supported these observations. Hydrogen bond profiles revealed that c_AMP_1 formed a moderate number of lipid-peptide hydrogen bonds throughout the simulation, averaging ~2–4 per frame in K. pneumoniae and P. aeruginosa (Fig 7A). H-bonding was more frequent in A. baumannii (~6 per frame), suggesting stronger surface adherence in this membrane. These interactions were primarily mediated by lysine and arginine residues at the peptide termini, forming transient electrostatic contacts with the polar headgroups. Corresponding tilt angle distributions (Fig 7B) showed that c_AMP_1 consistently aligned between 75° and 90°, indicative of a parallel orientation along the membrane surface. The angle range was broader in A. baumannii, with occasional excursions toward 60°, reflecting minor orientation shifts but no stable insertion.

Fig 7. Analysis of hydrogen bonding patterns and angular orientation (tilt) of c_AMP_1 and c_AMP_2 across three different bacterial membrane environments.

Fig 7

(A) Hydrogen bond counts of c_AMP_1 (B) Tilt angle distribution of c_AMP_1 (C) Hydrogen bond counts of c_AMP_2 (D) Tilt angle distribution of c_AMP_2 across A. baumannii, K. pneumoniae, and P. aeruginosa.

In contrast, c_AMP_2 established a significantly higher number of hydrogen bonds – averaging ~7–10 per frame across all membranes (Fig 7C). The strongest interaction was observed in A. baumannii, where c_AMP_2 maintained peak values between 8–12 H-bonds, while K. pneumoniae and P. aeruginosa exhibited slightly lower values (~6–8 per frame). These interactions were dominated by arginine and lysine residues engaging with lipid phosphate and glycerol groups, facilitating electrostatic stabilization. Tilt angle profiles (Fig 7D) revealed broader distributions for c_AMP_2, with values spanning 45° to 80°, reflecting a diagonally inserted orientation. The most stable and narrow angle range (~25°-35°) was observed in A. baumannii, supporting the observation of deeper insertion in this asymmetric membrane system. Together, the combination of high hydrogen bond frequency, sustained orientation, and membrane embedding suggests that c_AMP_2 may interact with the membrane more extensively than c_AMP_1 in silico, particularly in lipid environments with compositional asymmetry.

3.5. Residue-level interaction mapping and membrane perturbation analysis

To gain atomistic insights into how the peptides interact with bacterial membranes, residue-level contact maps were generated for c_AMP_1 and c_AMP_2 across all three systems (Fig 8). These maps visualize which amino acids maintain sustained proximity (<0.5 nm) to the membrane lipids over the 300 ns simulations.

Fig 8. Residue-level contact maps of c_AMP_1 and c_AMP_2 across three bacterial membranes.

Fig 8

Contact map of c_AMP_1 in (A) A. baumannii, (B) K. pneumoniae, and (C) P. aeruginosa; contact map of c_AMP_2 in (D) A. baumannii, (E) K. pneumoniae, and (F) P. aeruginosa.

For c_AMP_1, interaction hotspots were localized to a few basic residues at the N-terminal region, including Arg and Lys, especially in A. baumannii (Fig 8A) and K. pneumoniae (Fig 8B). However, in P. aeruginosa (Fig 8C), the contact density was notably reduced and fragmented, suggesting weaker and more transient peptide-lipid interactions. The limited and localized contact pattern aligns with previous observations of poor membrane embedding and low hydrogen bonding. In contrast, c_AMP_2 displayed widespread and persistent residue contacts spanning both the N- and C-terminal regions (Fig 8D-F). The key interacting residues included multiple lysines and arginines distributed along the peptide, supporting deep insertion and stable lipid engagement. In A. baumannii and K. pneumoniae, the contact intensity was high and continuous along the peptide backbone, suggesting strong and sustained electrostatic anchoring across the bilayer surface. Even in P. aeruginosa, where c_AMP_1 showed more limited and fragmented contacts, c_AMP_2 maintained broader interactions across the peptide, consistent with more extensive lipid engagement in this simulated system.

Membrane thickness maps further supported these interaction profiles (Fig 9). c_AMP_1 induced localized thinning beneath the peptide region in all three membranes (Fig 9A-C), with A. baumannii showing the most pronounced reduction (~1.1 Å), while K. pneumoniae and P. aeruginosa displayed only subtle deviations (<0.7 Å). These results are consistent with a surface-aligned conformation that perturbs the outer leaflet without significant penetration into the hydrophobic core. In contrast, c_AMP_2 induced notable bilayer deformation (Fig 9D-F), with thinning of ~2.1 Å in A. baumannii, ~1.8 Å in K. pneumoniae, and ~1.5 Å in P. aeruginosa. These reductions correspond to the high-contact zones seen in residue-level analysis, consistent with deeper insertion of c_AMP_2 and localized lipid compression within the simulated bilayers. Area per lipid (APL) analysis corroborated the extent of membrane perturbation caused by each peptide (Fig 10). c_AMP_1 resulted in modest APL expansion (Fig 10A-C), with a maximum increase of ~1.3% in A. baumannii, and less than 1% in K. pneumoniae and P. aeruginosa. This suggests minor adjustments in lateral lipid packing due to surface-level interaction. In contrast, c_AMP_2 led to significantly greater increases in APL across all membranes (Fig 10D-F), including ~3.2% in A. baumannii, ~2.4% in K. pneumoniae, and ~1.6% in P. aeruginosa. These data suggest that c_AMP_2 may perturb both vertical bilayer structure and lateral lipid organization to a greater extent than c_AMP_1 in the simulated systems, consistent with its deeper predicted insertion and stronger lipid engagement.

Fig 9. Membrane thickness profiles for c_AMP_1 and c_AMP_2 across bacterial membrane models.

Fig 9

Thickness variations in (A) A. baumannii, (B) K. pneumoniae, and (C) P. aeruginosa.

Fig 10. Area per lipid (APL) profiles of c_AMP_1 and c_AMP_2 across bacterial membranes.

Fig 10

(A–C) APL distributions of c_AMP_1 in A. baumannii, K. pneumoniae, and P. aeruginosa, respectively. (D–F) APL distributions of c_AMP_2 in A. baumannii, K. pneumoniae, and P. aeruginosa respectively.

3.6. Secondary structure evolution during simulations

The secondary structure dynamics of c_AMP_1 and c_AMP_2 were tracked throughout the 300 ns simulation to assess their structural integrity in membrane environments (Fig 11). Using DSSP analysis, we monitored the evolution of α-helicity and conformational transitions in A. baumannii, K. pneumoniae, and P. aeruginosa membranes.

Fig 11. Secondary structure dynamics of c_AMP_1 and c_AMP_2 as revealed by DSSP throughout the course of the simulation.

Fig 11

DSSP plots of c_AMP_1 in (A) A. baumannii, (B) K. pneumoniae, and (C) P. aeruginosa; DSSP plots of c_AMP_2 in (D) A. baumannii, (E) K. pneumoniae, and (F) P. aeruginosa.

c_AMP_1 maintained a stable α-helical conformation across all three systems, with minor fluctuations at the N- and C-terminal residues. In A. baumannii, the helical core (residues 10–30) was consistently preserved throughout the simulation, with transient unfolding events limited to terminal loops (Fig 11A). Similar trends were observed in K. pneumoniae and P. aeruginosa (Fig 11B and Fig 11C), where the core helix remained intact, and structural deviations were rare and short-lived. These results indicate that c_AMP_1 is structurally resilient in diverse membrane environments and adopts a conformation that supports surface-aligned interactions without significant destabilization.

In contrast, c_AMP_2 showed dynamic yet stable secondary structure behavior (Fig 11D-F). The central helix remained intact across all membranes, but conformational flexibility was evident in the terminal regions, particularly in K. pneumoniae (Fig 11E), where partial unwinding of the C-terminal end occurred after ~200 ns. Despite these fluctuations, the overall α-helical content remained high throughout the simulations. In A. baumannii (Fig 11D), the peptide retained a nearly continuous helical segment with minimal disruption, aligning with its deeper membrane insertion and stabilized orientation. P. aeruginosa (Fig 11F) exhibited slightly more flexible transitions in terminal regions but preserved the helical core, supporting sustained interaction with the bilayer. Collectively, these analyses suggest that both peptides preserve their secondary structure during simulated membrane engagement. c_AMP_1 appears rigid and helically stable, consistent with a surface-associated interaction mode, while c_AMP_2 displays predicted conformational flexibility that may facilitate deeper insertion and adaptive membrane interactions.

4. Discussion

The exploration of Indian marine microbiomes as a source of antimicrobial peptides has yielded significant and promising results that advance our understanding of natural peptide-based defenses in underexplored ecosystems. The identification of over 51,000 high-confidence c_AMPs through the integration of multiple machine learning tools reflects the value of ensemble prediction approaches in reducing false positives and enhancing prediction confidence. The stringency applied, which requires consensus across six independent classifiers, suggests that the shortlisted peptides are less likely to be artifacts of individual models and more likely to represent biologically plausible AMP candidates. This confidence is supported by the independent validation of each tool in its original publication; however, no additional in-study benchmarking against reference AMP datasets was performed, and this represents a limitation that future studies should address. This result is consistent with recent approaches to AMP discovery that emphasize high-throughput yet rigorously filtered pipelines, such as those employed by Santos-Júnior et al., who mined the global microbiome for AMPs using a deep learning approach and similarly reported that only approximately 0.2% of the predicted smORFs yielded confident AMP candidates [30]. The fact that a comparable high-confidence AMP yield (~0.21% of smORFs) was observed in Indian marine microbiomes underscores the untapped potential of this region’s biodiversity for bioactive compound discovery.

Further narrowing to ten membrane-penetrating c_AMPs based on physicochemical and structural criteria highlights the utility of incorporating known AMP features, such as cationicity, amphiphilicity, and residue composition (Arg and Trp), which are key determinants of membrane interaction [57]. These features are widely recognized in natural AMPs, such as LL-37 and magainin, for their ability to disrupt bacterial membranes [58]. Notably, the strong net charges and isoelectric points (>10) observed in peptides such as c_AMP_1 (net charge +11, pI 12.02) suggest robust electrostatic attraction to negatively charged bacterial membranes, particularly those of Gram-negative species such as A. baumannii and P. aeruginosa. The elevated amphiphilicity indices of several peptides (e.g., c_AMP_1: 1.59; c_AMP_5: 1.75) further suggest favourable insertion into lipid bilayers and subsequent disruption of membrane integrity.

It should be noted, however, that the application of a length cut-off of ≤50 amino acids and the requirement for both arginine and tryptophan residues inherently narrows the candidate set toward cationic, membrane-active peptides. This filter, while effective for identifying membrane-targeting candidates, may inadvertently exclude other biologically relevant AMP classes such as anionic peptides, proline-rich AMPs, or peptides that act through intracellular mechanisms. This represents a limitation of the current pipeline, and future studies may benefit from broader compositional filters to capture the full diversity of AMP types present in marine metagenomic datasets.

The in silico safety profiling of the ten shortlisted peptides using ToxinPred 3.0 and HemoPI 2.0 revealed that all candidates were predicted as non-toxic, while hemolytic activity predictions indicated variable but moderate predicted HC50 values ranging from 18.3 to 126.4 μM. While these results suggest a potentially acceptable safety window, particularly for c_AMP_2 and c_AMP_7 which showed lower predicted hemolytic potency, in silico hemolysis predictions have inherent limitations and experimental validation through red blood cell hemolysis assays and mammalian cytotoxicity testing remains essential before any safety conclusions can be drawn.

AlphaFold-based structural predictions provided crucial insights into the 3D conformations of the selected peptides, particularly c_AMP_1 and c_AMP_2. The predominance of α-helical structures in c_AMP_1 is in line with canonical membrane-active peptides, which often adopt such conformations upon interaction with lipid bilayers [59]. The helical wheel diagrams displayed a typical amphipathic pattern, with hydrophobic amino acids grouped on one side of the helix and positively charged residues on the opposite side, an arrangement that is consistent with membrane association and interaction in bacterial cells. Despite being only partially helical, c_AMP_2 maintained its amphipathic nature, which is crucial for membrane engagement. This suggests that a combination of incomplete helicity and distinct charge distribution can still promote effective membrane interaction, an observation consistent with earlier reports on functionally active yet structurally flexible AMPs [60].

Molecular dynamics simulations in three membrane environments representing P. aeruginosa, A. baumannii, and K. pneumoniae revealed important dynamics of peptide-membrane interactions. c_AMP_1 displayed rapid stabilization (RMSD ~1.2–1.3 Å), particularly in P. aeruginosa, which is indicative of conformational rigidity and persistent structural integrity during membrane engagement. Its low RMSF values across the core helix further support structural stability, while increased SASA implies surface localization with effective membrane binding rather than deep insertion. In contrast, c_AMP_2 exhibited higher RMSD (2.2–2.5 Å) and RMSF, especially in the C-terminal region, reflecting greater flexibility and mobility within the bilayer. Its lower SASA values suggest deeper embedding into the membrane, likely due to its more compact conformation and hydrophobic distribution. These contrasting behaviors illustrate the distinct membrane interaction modes the two peptides may adopt, ranging from surface-associated orientation to deeper membrane embedding, both of which have been documented in membrane-active peptides such as melittin and indolicidin [61–63].

The hydrogen bonding profiles between the peptides and the lipid membranes further corroborate these distinct interaction patterns. c_AMP_1 formed ~2–6 hydrogen bonds per frame, with peak values in A. baumannii (~6/frame), supporting its stable yet superficial interaction with the membrane headgroups. These interactions predominantly involve arginine and lysine side chains engaging with phosphate or carbonyl oxygens of lipid headgroups, a mechanism also observed in other high-charge AMPs, such as defensins [64–66]. Although c_AMP_2 formed a consistently higher number of H-bonds (~7–12/frame), dominated by Arg and Lys sidechains, it maintained stable contacts deeper in the bilayer, suggesting that van der Waals and hydrophobic interactions play a greater role in its anchoring and membrane embedding.

Peptide tilt angles relative to the membrane normal provided insights into peptide orientation states during embedding. c_AMP_1 showed a consistent tilt range of ~75°-90°, indicating parallel surface alignment, which is consistent with a surface-associated orientation reminiscent of carpet-like interaction models. c_AMP_2 showed broader tilt values (~45°-80°), suggesting a more deeply embedded, diagonal orientation reminiscent of insertion-type interaction models observed in longer or more hydrophobic AMPs [13]. The observed angles also varied slightly between the membranes, with the greatest tilting occurring in the K. pneumoniae system, indicating that lipid composition influences peptide orientation and possibly efficacy.

An important consideration in interpreting the cross-species simulation results is that the three membrane models employed in this study are not architecturally equivalent. The A. baumannii model incorporates an asymmetric outer membrane containing Lipid A/LPS, whereas the K. pneumoniae and P. aeruginosa models represent symmetric inner membrane phospholipid bilayers lacking LPS. LPS is known to exert a significant influence on peptide binding, insertion depth, and membrane perturbation through its bulky polysaccharide chains and strong electrostatic interactions with cationic peptides (Jiang et al., 2020; Gong et al., 2023). Consequently, the observed differences in peptide behavior across the three membrane systems reflect both species-specific lipid compositions and the fundamentally different membrane architectures modelled. Direct quantitative comparisons of interaction metrics across systems should therefore be interpreted with caution, and this represents a limitation of the current comparative analysis. Future studies employing equivalent outer membrane models incorporating species-specific LPS compositions for all three organisms would enable more rigorous cross-species comparisons.

Residue-lipid contact maps further revealed that for c_AMP_1, arginine and tryptophan residues were key in anchoring the peptide to membrane headgroups, forming consistent contacts over the simulation period. This preference for cation-π and hydrogen bonding interactions with phospholipid headgroups reflects conserved AMP behavior, where these residues facilitate initial binding and destabilization [67–69]. In contrast, c_AMP_2 exhibited a broader interaction footprint, engaging mid-helix residues with the lipid tail region, pointing to a more deeply embedded orientation in the simulations; whether this translates into actual membrane permeabilization cannot be determined from these structural simulations alone and would require dedicated experimental assays.

Membrane thickness and area per lipid analyses revealed biophysical changes induced by peptide interactions. c_AMP_1 caused mild thinning (~1.1 Å) beneath the contact zone in A. baumannii, and <0.7 Å in K. pneumoniae and P. aeruginosa. This result aligns with its higher SASA and lower tilt. c_AMP_2 induced more pronounced thinning (~2.1 Å in A. baumannii, ~ 1.8 Å in K. pneumoniae) and increased the area per lipid by ~3.2% in A. baumannii, ~ 2.4% in K. pneumoniae, and ~1.6% in P. aeruginosa. These metrics mirror findings from MD simulations of other membrane-active AMPs, such as MSI-594, which induce membrane thinning and lateral expansion as part of their predicted interaction profile [13,70].

Secondary structure evolution using DSSP during the simulations revealed that c_AMP_1 showed partial helical loss, especially in P. aeruginosa, where helicity declined after ~150 ns, underscoring its conformational rigidity and structural resilience, which are critical for sustained membrane interaction. c_AMP_2 retained >80% helical content across all membranes, with minor terminal flexibility in K. pneumoniae and P. aeruginosa with ~65–70% helical content interspersed with coil and turn motifs, especially at terminal regions. This plasticity may facilitate membrane penetration and adaptation to various lipid environments, as observed in structurally flexible AMPs such as protegrins [71]. Collectively, these structural dynamics highlight the predicted biophysical divergence between the two peptides, suggesting they may adopt distinct membrane interaction modes, pending experimental validation.

While this study presents a comprehensive in silico characterization of candidate AMPs, the absence of experimental validation remains a notable limitation. Future studies should prioritize wet-lab validation of the lead candidates, c_AMP_1 and c_AMP_2, through: (i) minimum inhibitory concentration (MIC) assays against representative ESKAPE strains, (ii) membrane permeabilization assays using fluorescent indicators such as SYTOX Green or propidium iodide, (iii) liposome-based membrane leakage assays to confirm bilayer disruption, and (iv) hemolysis and cytotoxicity assays on mammalian cell lines such as RBCs and HEK293 to evaluate selectivity and safety. These experiments will be essential to confirm the predicted antimicrobial potential identified through computational analyses.

Several inherent limitations of the single-peptide MD simulations employed in this study warrant explicit acknowledgement. While the 300 ns all-atom simulations provide detailed insights into geometric preferences, orientation states, and lipid perturbation patterns of individual peptides, they cannot, in isolation, establish functional outcomes such as pore formation, membrane permeabilization, or bactericidal activity. Single-peptide simulations do not capture the cooperative behavior of multiple peptides interacting simultaneously with a membrane, which is often a prerequisite for functional membrane disruption. Furthermore, each simulation system was run as a single trajectory, which limits statistical confidence, and the 300 ns timescale, while extensive for single-peptide systems, may not fully capture slow membrane reorganization events, particularly in the asymmetric LPS-containing outer membrane model of A. baumannii, where lipid rearrangement and peptide-induced perturbations may occur on longer timescales than those sampled here. Future studies employing multiple replicates or enhanced sampling methods would provide stronger statistical support and deeper insights into these dynamics. Consequently, all observations from the MD simulations in this study are interpreted as predicted interaction modes and biophysical characterization rather than as demonstrated antimicrobial mechanisms, and experimental validation remains essential before any functional claims can be made.

It is important to acknowledge that the machine learning tools employed in this study were primarily trained on general AMP datasets, which may underrepresent experimentally validated antitubercular peptides, potentially limiting the sensitivity of the pipeline for Mycobacterium-active peptides. While the primary focus of this study is on Gram-negative ESKAPE pathogens, an exploratory screening of the ten shortlisted candidates using AntiTbPred [72] revealed that all ten peptides were predicted as potential anti-tubercular peptides, with prediction scores ranging from 0.26 to 1.72 (Table E in S1 File). These findings are presented as exploratory observations and should not be interpreted as confirmed anti-mycobacterial activity, which would require dedicated experimental validation including MIC assays against Mycobacterium tuberculosis strains. Future studies are recommended to benchmark the pipeline against specialized resources such as AntiTbPdb [73] to more rigorously assess its sensitivity for anti-mycobacterial peptide discovery.

To contextualize the translational potential of the lead candidates, similarity searches were performed against THPdb2 [74], a curated database of FDA-approved therapeutic peptides and proteins. No statistically significant sequence similarity was detected for either c_AMP_1 (E-value: 1.7) or c_AMP_2 (E-value: 6.2), confirming their structural distinctiveness from currently approved therapeutics (Table F in S1 File). Notably, both candidates fall within the ‘Long Peptides (21–50 AA)’ category of THPdb2, which encompasses 45 unique FDA-approved therapeutic peptides, indicating that their length profile is consistent with clinically approved peptide therapeutics. Furthermore, their strongly cationic nature, amphipathic architecture, and predicted membrane-targeting properties align well with the physicochemical characteristics associated with approved antimicrobial peptide therapeutics. Collectively, these observations indicate that c_AMP_1 and c_AMP_2 possess physicochemical attributes broadly consistent with those of known membrane-active and clinically approved peptides. In the absence of experimental data, however, these similarities should be regarded as preliminary, and the two peptides are best viewed as computational starting points that will require extensive experimental validation before any therapeutic potential can be established.

5. Conclusion

Over 51,000 high-confidence c_AMPs were identified from Indian marine microbiomes using a consensus-based approach across six machine learning classifiers, suggesting a reduction in the number of false positives. Ten membrane-active c_AMPs were shortlisted on the basis of key properties, such as their cationicity, amphiphilicity, and net positive charge, which are essential for bacterial membrane targeting. Structural predictions revealed amphipathic α-helices in top peptides such as c_AMP_1, supporting their predicted potential for membrane insertion and perturbation in silico. MD simulations revealed distinct membrane interaction modes: c_AMP_1 remained surface-associated, while c_AMP_2 adopted a more deeply embedded orientation, suggesting distinct biophysical interaction profiles. The peptides induced membrane thinning and area expansion, especially c_AMP_2, suggesting predicted biophysical perturbation of the simulated bacterial membrane models. c_AMP_1 exhibited stable α-helicity and a low RMSD, whereas c_AMP_2 showed flexible secondary structures, indicating adaptability to different membrane environments. Arginine and tryptophan residues are predicted to play important roles in membrane binding and anchoring in the simulated systems, which is consistent with established AMP interaction models. Taken together, these computational findings point to the predicted membrane-active potential of marine-derived candidate AMPs against Gram-negative ESKAPE pathogens and underscore the need for experimental validation of their antimicrobial activity and safety, including MIC assays, membrane permeabilization studies, and cytotoxicity testing in relevant models, before any functional or therapeutic conclusions can be drawn.

Supporting information

S1 File. Supporting tables and figures referenced in the main text.

(DOCX)

pone.0353985.s001.docx (1.7MB, docx)
S2 File. List of high-confidence antimicrobial peptides (c_AMPs) predicted from Indian marine metagenomic datasets.

(ZIP)

pone.0353985.s002.zip (2.3MB, zip)

Acknowledgments

The authors would like to thank Manipal School of Life Sciences, Manipal Academy of Higher Education for providing necessary facilities to carry out this work. The authors also acknowledge the high-performance computing facility and storage provided by CDAC-MAHE, Param Utkarsh facility.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The authors also acknowledge the funding from the Anusandhan National Research Foundation (Sanction Order: ANRF/ECRG/2024/003501/LS) for providing Prime Minister Early Career Research Grant to BD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Coque TM, Cantón R, Pérez-Cobas AE, Fernández-de-Bobadilla MD, Baquero F. Antimicrobial Resistance in the Global Health Network: Known Unknowns and Challenges for Efficient Responses in the 21st Century. Microorganisms. 2023;11(4):1050. doi: 10.3390/MICROORGANISMS11041050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet. 2024;404(10459):1199–226. doi: 10.1016/S0140-6736(24)01867-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Irfan M, Almotiri A, AlZeyadi ZA. Antimicrobial Resistance and Its Drivers-A Review. Antibiotics (Basel). 2022;11(10):1362. doi: 10.3390/antibiotics11101362 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sulis G, Sayood S, Gandra S. Antimicrobial resistance in low- and middle-income countries: current status and future directions. Expert Rev Anti Infect Ther. 2022;20(2):147–60. doi: 10.1080/14787210.2021.1951705 [DOI] [PubMed] [Google Scholar]
  • 5.Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. doi: 10.1016/S0140-6736(21)02724-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ravi K, Singh B. ESKAPE: Navigating the Global Battlefield for Antimicrobial Resistance and Defense in Hospitals. Bacteria. 2024;3(2):76–98. doi: 10.3390/bacteria3020006 [DOI] [Google Scholar]
  • 7.El-Kady R, Karoma S, Al Atrouni A. Multidrug-resistant Gram-negative ESKAPE pathogens from a tertiary-care hospital: prevalence and risk factors. Egypt J Med Microbiol. 2022;31(3):135–42. [Google Scholar]
  • 8.Kharat AS, Makwana N, Nasser M, Gayen S, Yadav B, Kumar D, et al. Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India. Int J Antimicrob Agents. 2024;63(5):107125. doi: 10.1016/j.ijantimicag.2024.107125 [DOI] [PubMed] [Google Scholar]
  • 9.Savitskaya A, Masso-Silva J, Haddaoui I, Enany S. Exploring the arsenal of antimicrobial peptides: Mechanisms, diversity, and applications. Biochimie. 2023;214(Pt B):216–27. doi: 10.1016/j.biochi.2023.07.016 [DOI] [PubMed] [Google Scholar]
  • 10.Ali M, Garg A, Srivastava A, Arora PK. The role of antimicrobial peptides in overcoming antibiotic resistance. The Microbe. 2025;7:100337. doi: 10.1016/j.microb.2025.100337 [DOI] [Google Scholar]
  • 11.Benfield AH, Henriques ST. Mode-of-Action of Antimicrobial Peptides: Membrane Disruption vs. Intracellular Mechanisms. Front Med Technol. 2020;2:610997. doi: 10.3389/FMEDT.2020.610997 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Drayton M, Deisinger JP, Ludwig KC, Raheem N, Müller A, Schneider T. Host defense peptides: dual antimicrobial and immunomodulatory action. International Journal of Molecular Sciences. 2021;22(20):11172. doi: 10.3390/IJMS222011172 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ma X, Wang Q, Ren K, Xu T, Zhang Z, Xu M, et al. A Review of Antimicrobial Peptides: Structure, Mechanism of Action, and Molecular Optimization Strategies. Fermentation. 2024;10(11):540. doi: 10.3390/fermentation10110540 [DOI] [Google Scholar]
  • 14.Johnson TS, Deber CM. Protection or Destruction: The LL-37/HNP1 Cooperativity Switch. Biophys J. 2020;119(12):2370–1. doi: 10.1016/j.bpj.2020.10.046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Srinivasan R, Kannappan A, Shi C, Lin X. Marine Bacterial Secondary Metabolites: A Treasure House for Structurally Unique and Effective Antimicrobial Compounds. Mar Drugs. 2021;19(10):530. doi: 10.3390/md19100530 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Torres MDT, Brooks EF, Cesaro A, Sberro H, Gill MO, Nicolaou C, et al. Mining human microbiomes reveals an untapped source of peptide antibiotics. Cell. 2024;187(19):5453–5467.e15. doi: 10.1016/j.cell.2024.07.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Behera BK, Dehury B, Rout AK, Patra B, Mantri N, Chakraborty HJ, et al. Metagenomics study in aquatic resource management: Recent trends, applied methodologies and future needs. Gene Reports. 2021;25:101372. doi: 10.1016/j.genrep.2021.101372 [DOI] [Google Scholar]
  • 18.Parida PK, Behera BK, Dehury B, Rout AK, Sarkar DJ, Rai A, et al. Community structure and function of microbiomes in polluted stretches of river Yamuna in New Delhi, India, using shotgun metagenomics. Environ Sci Pollut Res Int. 2022;29(47):71311–25. doi: 10.1007/s11356-022-20766-1 [DOI] [PubMed] [Google Scholar]
  • 19.Chen J, Jia Y, Sun Y, Liu K, Zhou C, Liu C, et al. Global marine microbial diversity and its potential in bioprospecting. Nature. 2024;633(8029):371–9. doi: 10.1038/s41586-024-07891-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kanaujia KA, Wagh S, Pandey G, Phatale V, Khairnar P, Kolipaka T, et al. Harnessing marine antimicrobial peptides for novel therapeutics: A deep dive into ocean-derived bioactives. Int J Biol Macromol. 2025;307(Pt 3):142158. doi: 10.1016/j.ijbiomac.2025.142158 [DOI] [PubMed] [Google Scholar]
  • 21.Kathiresan K, Mohan S. Coastal biodiversity of India. Coastal agriculture and climate change. 2021:129–35. doi: 10.1201/9781003245285-13/COASTAL-BIODIVERSITY-INDIA-KATHIRESAN-MOHAN [DOI] [Google Scholar]
  • 22.Behera BK, Chakraborty HJ, Patra B, Rout AK, Dehury B, Das BK, et al. Metagenomic Analysis Reveals Bacterial and Fungal Diversity and Their Bioremediation Potential From Sediments of River Ganga and Yamuna in India. Front Microbiol. 2020;11:556136. doi: 10.3389/fmicb.2020.556136 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Rout AK, Dehury B, Parida PK, Sarkar DJ, Behera B, Das BK, et al. Taxonomic profiling and functional gene annotation of microbial communities in sediment of river Ganga at Kanpur, India: insights from whole-genome metagenomics study. Environ Sci Pollut Res Int. 2022;29(54):82309–23. doi: 10.1007/s11356-022-21644-6 [DOI] [PubMed] [Google Scholar]
  • 24.Wang G, Vaisman II, van Hoek ML. Machine Learning Prediction of Antimicrobial Peptides. Methods in Molecular Biology. 2022;2405:1–37. doi: 10.1007/978-1-0716-1855-4_1/FIGURES/3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Szymczak P, Szczurek E. Artificial intelligence-driven antimicrobial peptide discovery. Curr Opin Struct Biol. 2023;83. doi: 10.1016/j.sbi.2023.102733 [DOI] [PubMed] [Google Scholar]
  • 26.Melo MCR, Maasch JRMA, de la Fuente-Nunez C. Accelerating antibiotic discovery through artificial intelligence. Communications Biology. 2021;4(1):1–13. doi: 10.1038/s42003-021-02586-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Brizuela CA, Liu G, Stokes JM, de la Fuente-Nunez C. AI Methods for Antimicrobial Peptides: Progress and Challenges. Microb Biotechnol. 2025;18(1):e70072. doi: 10.1111/1751-7915.70072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Al-Omari AM, Akkam YH, Zyout A, Younis S, Tawalbeh SM, Al-Sawalmeh K, et al. Accelerating antimicrobial peptide design: Leveraging deep learning for rapid discovery. PLoS One. 2024;19(12):e0315477. doi: 10.1371/journal.pone.0315477 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Veltri D, Kamath U, Shehu A. Deep learning improves antimicrobial peptide recognition. Bioinformatics. 2018;34(16):2740–7. doi: 10.1093/bioinformatics/bty179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Santos-Júnior CD, Torres MDT, Duan Y, Rodríguez del Río Á, Schmidt TSB, Chong H. Discovery of antimicrobial peptides in the global microbiome with machine learning. Cell. 2024;187(14):3761–3778.e16. doi: 10.1016/j.cell.2024.05.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114. doi: 10.1093/BIOINFORMATICS/BTU170 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Li D, Luo R, Liu C-M, Leung C-M, Ting H-F, Sadakane K, et al. MEGAHIT v1.0: A fast and scalable metagenome assembler driven by advanced methodologies and community practices. Methods. 2016;102:3–11. doi: 10.1016/j.ymeth.2016.02.020 [DOI] [PubMed] [Google Scholar]
  • 33.Hyatt D, Chen G-L, Locascio PF, Land ML, Larimer FW, Hauser LJ. Prodigal: prokaryotic gene recognition and translation initiation site identification. BMC Bioinformatics. 2010;11:119. doi: 10.1186/1471-2105-11-119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation sequencing data. Bioinformatics. 2012;28(23):3150–2. doi: 10.1093/bioinformatics/bts565 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Li C, Sutherland D, Hammond SA, Yang C, Taho F, Bergman L, et al. AMPlify: attentive deep learning model for discovery of novel antimicrobial peptides effective against WHO priority pathogens. BMC Genomics. 2022;23(1):77. doi: 10.1186/s12864-022-08310-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Fingerhut LCHW, Miller DJ, Strugnell JM, Daly NL, Cooke IR. ampir: an R package for fast genome-wide prediction of antimicrobial peptides. Bioinformatics. 2021;36(21):5262–3. doi: 10.1093/bioinformatics/btaa653 [DOI] [PubMed] [Google Scholar]
  • 37.Lin TT, Yang LY, Lu IH, Cheng WC, Hsu ZR, Chen SH, et al. AI4AMP: an antimicrobial peptide predictor using physicochemical property-based encoding method and deep learning. mSystems. 2021;6(6). doi: 10.1128/MSYSTEMS.00299-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lawrence TJ, Carper DL, Spangler MK, Carrell AA, Rush TA, Minter SJ, et al. amPEPpy 1.0: a portable and accurate antimicrobial peptide prediction tool. Bioinformatics. 2021;37(14):2058–60. doi: 10.1093/BIOINFORMATICS/BTAA917 [DOI] [PubMed] [Google Scholar]
  • 39.Su X, Xu J, Yin Y, Quan X, Zhang H. Antimicrobial peptide identification using multi-scale convolutional network. BMC Bioinformatics. 2019;20(1):730. doi: 10.1186/s12859-019-3327-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kumar N, Du Z, Li Y. pLM4CPPs: Protein Language Model-Based Predictor for Cell Penetrating Peptides. J Chem Inf Model. 2025. doi: 10.1021/ACS.JCIM.4C01338 [DOI] [PubMed] [Google Scholar]
  • 41.Kumar V, Agrawal P, Kumar R, Bhalla S, Usmani SS, Varshney GC, et al. Prediction of Cell-Penetrating Potential of Modified Peptides Containing Natural and Chemically Modified Residues. Front Microbiol. 2018;9:725. doi: 10.3389/fmicb.2018.00725 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Bajiya N, Najrin S, Kumar P, Choudhury S, Tomer R, Raghava GPS. CPPsite3: An updated large repository of experimentally validated cell-penetrating peptides. Drug Discov Today. 2025;30(8):104421. doi: 10.1016/j.drudis.2025.104421 [DOI] [PubMed] [Google Scholar]
  • 43.Pirtskhalava M, Amstrong AA, Grigolava M, Chubinidze M, Alimbarashvili E, Vishnepolsky B, et al. DBAASP v3: database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics. Nucleic Acids Res. 2021;49(D1):D288–97. doi: 10.1093/nar/gkaa991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rathore AS, Choudhury S, Arora A, Tijare P, Raghava GPS. ToxinPred 3.0: An improved method for predicting the toxicity of peptides. Comput Biol Med. 2024;179. doi: 10.1016/j.compbiomed.2024.108926 [DOI] [PubMed] [Google Scholar]
  • 45.Rathore AS, Kumar N, Choudhury S, Mehta NK, Raghava GPS. Prediction of hemolytic peptides and their hemolytic concentration. Commun Biol. 2025;8(1):176. doi: 10.1038/s42003-025-07615-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493–500. doi: 10.1038/s41586-024-07487-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Gazerani G, Piercey LR, Reema S, Wilson KA. Examining the biophysical properties of the inner membrane of gram-negative ESKAPE pathogens. J Chem Inf Model. 2025;65:1453–64. doi: 10.1021/ACS.JCIM.4C01457 [DOI] [PubMed] [Google Scholar]
  • 48.Jiang X, Yang K, Yuan B, Han M, Zhu Y, Roberts KD, et al. Molecular dynamics simulations informed by membrane lipidomics reveal the structure-interaction relationship of polymyxins with the lipid A-based outer membrane of Acinetobacter baumannii. J Antimicrob Chemother. 2020;75(12):3534–43. doi: 10.1093/jac/dkaa376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lee J, Cheng X, Swails JM, Yeom MS, Eastman PK, Lemkul JA, et al. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. J Chem Theory Comput. 2016;12(1):405–13. doi: 10.1021/acs.jctc.5b00935 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26(16):1701–18. doi: 10.1002/jcc.20291 [DOI] [PubMed] [Google Scholar]
  • 51.Klauda JB, Venable RM, Freites JA, O’Connor JW, Tobias DJ, Mondragon-Ramirez C, et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J Phys Chem B. 2010;114(23):7830–43. doi: 10.1021/jp101759q [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Mark P, Nilsson L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. Journal of Physical Chemistry A. 2001;105(43):9954–60. doi: 10.1021/jp003020w [DOI] [Google Scholar]
  • 53.Hatch HW, Hall SW, Errington JR, Shen VK. Improving the efficiency of Monte Carlo simulations of ions using expanded grand canonical ensembles. J Chem Phys. 2019;151(14):144109. doi: 10.1063/1.5123683 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Humphrey W, Dalke A, Schulten K. VMD: Visual Molecular Dynamics. 1996. [DOI] [PubMed] [Google Scholar]
  • 55.Buchoux S. FATSLiM: a fast and robust software to analyze MD simulations of membranes. Bioinformatics. 2017;33(1):133–4. doi: 10.1093/bioinformatics/btw563 [DOI] [PubMed] [Google Scholar]
  • 56.Mercadante D, Gräter F, Daday C. CONAN: A Tool to Decode Dynamical Information from Molecular Interaction Maps. Biophys J. 2018;114(6):1267–73. doi: 10.1016/j.bpj.2018.01.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Sarkar T, Vignesh SR, Kumar Sundaravadivelu P, Thummer RP, Satpati P, Chatterjee S. De Novo Design of Tryptophan Containing Broad-Spectrum Cationic Antimicrobial Octapeptides. ChemMedChem. 2025;20(2):e202400566. doi: 10.1002/CMDC.202400566 [DOI] [PubMed] [Google Scholar]
  • 58.Gong H, Hu X, Zhang L, Fa K, Liao M, Liu H, et al. How do antimicrobial peptides disrupt the lipopolysaccharide membrane leaflet of Gram-negative bacteria? J Colloid Interface Sci. 2023;637:182–92. doi: 10.1016/j.jcis.2023.01.051 [DOI] [PubMed] [Google Scholar]
  • 59.Kabelka I, Vácha R. Advances in Molecular Understanding of α-Helical Membrane-Active Peptides. Acc Chem Res. 2021;54(9):2196–204. doi: 10.1021/acs.accounts.1c00047 [DOI] [PubMed] [Google Scholar]
  • 60.Bui TPH, Doan NH, Le HB, Vu DH, Luong XH. The amphipathic design in helical antimicrobial peptides. ChemMedChem. 2024;19(7):e202300480. doi: 10.1002/CMDC.202300480 [DOI] [PubMed] [Google Scholar]
  • 61.Kumar P, Kizhakkedathu JN, Straus SK. Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. Biomolecules. 2018;8(1):4. doi: 10.3390/BIOM8010004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Hong J, Lu X, Deng Z, Xiao S, Yuan B, Yang K. How Melittin Inserts into Cell Membrane: Conformational Changes, Inter-Peptide Cooperation, and Disturbance on the Membrane. Molecules. 2019;24(9):1775. doi: 10.3390/molecules24091775 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Sun L, Wang S, Tian F, Zhu H, Dai L. Organizations of melittin peptides after spontaneous penetration into cell membranes. Biophys J. 2022;121(22):4368–81. doi: 10.1016/j.bpj.2022.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Schmidt NW, Mishra A, Lai GH, Davis M, Sanders LK, Tran D. Criterion for amino acid composition of defensins and antimicrobial peptides based on geometry of membrane destabilization. J Am Chem Soc. 2011;133(17):6720–7. doi: 10.1021/JA200079A [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Kooijman EE, Tieleman DP, Testerink C, Munnik T, Rijkers DTS, Burger KNJ, et al. An electrostatic/hydrogen bond switch as the basis for the specific interaction of phosphatidic acid with proteins. J Biol Chem. 2007;282(15):11356–64. doi: 10.1074/jbc.M609737200 [DOI] [PubMed] [Google Scholar]
  • 66.Graber Z, Kwarteng DO, Lange SM, Koukanas Y, Khalifa H, Mutambuze JW. The electrostatic basis of diacylglycerol pyrophosphate—protein interaction. Cells. 2022;11(2):290. doi: 10.3390/cells11020290 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Khandelia H, Kaznessis YN. Cation-pi interactions stabilize the structure of the antimicrobial peptide indolicidin near membranes: molecular dynamics simulations. J Phys Chem B. 2007;111(1):242–50. doi: 10.1021/jp064776j [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Su Y, Li S, Hong M. Cationic membrane peptides: atomic-level insight of structure-activity relationships from solid-state NMR. Amino Acids. 2013;44(3):821–33. doi: 10.1007/s00726-012-1421-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Necula G, Bacalum M, Radu M. Interaction of tryptophan- and arginine-rich antimicrobial peptide with E. coli outer membrane—A molecular simulation approach. International Journal of Molecular Sciences. 2023;24(3). doi: 10.3390/ijms24032005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Mukherjee S, Kar RK, Nanga RPR, Mroue KH, Ramamoorthy A, Bhunia A. Accelerated molecular dynamics simulation analysis of MSI-594 in a lipid bilayer. Phys Chem Chem Phys. 2017;19(29):19289–99. doi: 10.1039/c7cp01941f [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Zhuang Y, Quirk S, Stover ER, Bureau HR, Allen CR, Hernandez R. Tertiary Plasticity Drives the Efficiency of Enterocin 7B Interactions with Lipid Membranes. J Phys Chem B. 2024;128(9):2100–13. doi: 10.1021/acs.jpcb.3c08199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Usmani SS, Bhalla S, Raghava GPS. Prediction of Antitubercular Peptides From Sequence Information Using Ensemble Classifier and Hybrid Features. Front Pharmacol. 2018;9:954. doi: 10.3389/fphar.2018.00954 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Usmani SS, Kumar R, Kumar V, Singh S, Raghava GPS. AntiTbPdb: a knowledgebase of anti-tubercular peptides. Database (Oxford). 2018;2018:bay025. doi: 10.1093/database/bay025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS One. 2017;12(7):e0181748. doi: 10.1371/journal.pone.0181748 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Salman Sadullah Usmani

10 Feb 2026

-->PONE-D-25-55465-->-->Uncovering dual-mechanism antimicrobial peptides from the Indian marine microbiome to combat multidrug-resistant ESKAPE Pathogens-->-->PLOS One

Dear Dr. Dehury,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 27 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Salman Sadullah Usmani, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

-->1. When submitting your revision, we need you to address these additional requirements.-->--> -->-->Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at -->-->https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and -->-->https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf-->--> -->-->2. Please note that PLOS One has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.-->--> -->-->3. Thank you for stating the following in the Acknowledgments Section of your manuscript: -->-->The authors would like to thank Manipal School of Life Sciences, Manipal Academy of Higher Education for providing necessary facilities to carry out this work. The authors also acknowledge the high-performance computing facility and storage provided by CDAC-MAHE, Param Utkarsh facility. The authors also acknowledge the funding Anusandhan National Research Foundation (Sanction Order: ANRF/ECRG/2024/003501/LS) for providing Prime Minister Early Career Research Grant to BD.-->--> -->-->We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. -->-->Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: -->-->The author(s) received no specific funding for this work. -->--> -->-->Please include your amended statements within your cover letter; we will change the online submission form on your behalf.-->--> -->-->4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments:

The manuscript in its current form overstates the experimental implications of what is fundamentally a computational study. In the current form, manuscript overstates the functional activity of the peptides; all claims should be moderated. The title and several statements in the abstract, results, and discussion should be revised to explicitly indicate that this is an in silico investigation and that the reported antimicrobial activities are predicted rather than demonstrated. The absence of any wet-lab validation is a significant limitation and either wet-lab experiments should be done or more clearly acknowledged, accompanied by a concrete experimental roadmap (e.g., MIC testing, membrane leakage, and cytotoxicity assays). The rationale for selecting only two peptides for molecular dynamics simulations is insufficiently justified and should either be clarified or expanded to include additional candidates. Furthermore, given the reliance on Arg/Trp-based rules for cell-penetrating behavior, the authors should cross-validate their shortlisted peptides using established CPP resources such as CPPsite 2.0, CellPPDmod. In addition, many experimentally validated antitubercular peptides are absent from general AMP repositories used to train current predictors, which can affect sensitivity for Mycobacterium-active peptides. Therefore, benchmarking against specialized datasets and tools such as AntiTbPdb and AntiTbPred would also help assess the sensitivity of their pipeline, particularly for anti-mycobacterial relevance. Finally, the translational framing would be strengthened by comparing the lead peptides with characteristics of clinically approved therapeutics using curated resources such as THPdb, SATPdb etc. and by more deeply engaging with recent marine AMP and membrane-modeling literature.

-->--> -->-->[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions-->

-->Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Partly

**********

-->2. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

Reviewer #2: N/A

Reviewer #3: No

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: Dear Author,

The article titled "Uncovering dual-mechanism antimicrobial peptides from the Indian marine microbiome

to combat multidrug-resistant ESKAPE Pathogens" was reviewed. This article provides useful information for its readers. Please make the following correction:

Some references are outdated, please use the new references.

Kind regards

Reviewer #2: The authors analyze five Indian marine metagenomic datasets to identify antimicrobial peptide candidates using six prediction tools. After applying additional filters based on peptide length, amino acid composition, and predicted cell-penetrating properties, they reduce the set to ten peptides. Two of these are then selected for molecular dynamics simulations with Gram-negative membrane models. The differences in how these peptides interact with the membranes are described in the Results and discussed as possible dual mechanisms. While the overall workflow is logical and clearly presented, several aspects of the methadology and interpretation require clarification and more cautious framing.

The Methods section should clearly state (i) the total number of peptides advanced to MD simulations, (ii)Whether c_AMP_1 and c_AMP_2 were the only peptides simulated, and (iii) the criteria used to select them ( Charge, hydrophobic moment, predictable activity, or structural diversity).

The claim of "dual mechanisms" seems somewhat stronger than what is directly supported by the simulation results. The observed differences mainly show distinct membrane interaction behaviors in the MD simulations, rather than clearly separate antimicrobial mechanisms. The reported analyses describe interaction patterns but do not directly demonstrate effects such as pore formation or membrane permeabilization. The authors may consider softening the wording in the Discussion and Conclusions to better reflect the in silico scope of the results.

After the six prediction tools are applied, the candidate peptides are further filtered by length (≤ 50 amino acids) and by requiring the presence of both arginine and tryptophan residues. These additional filters narrow the set toward cationic, membrane-active peptides and likely exclude other AMP types. It would be helpful if the authors briefly note this limitation in the Discussion.

The manuscript states that agreement across six prediction tools produces a high-confidence AMP set, but no quantitative validation or benchmarking results are shown to support this claim (for example, testing on known AMP and non-AMP reference datasets). The authors should either provide validation metrics or soften this statement. In addition, a few MD simulation details could be described more clearly to support reproducibility.

For reproducibility, a few MD setup details should be clarified. Please specify the initial peptide placement and orientation relative to the membrane, whether simulations were run with replicates or single trajectories, and the criteria used to define peptide-lipid hydrogen bonds. A brief note on possible timescale limitations for the membrane simulations, especially LPS-containing models, would also help interpretation.

The paper presents the results as if they directly apply to treating multidrug-resistant ESKAPE pathogens and suggests therapeutic potential in the Title, Abstract, and Conclusions. However, the study is entirely computational and does not include experimental validation. The wording should be revised to clearly reflect that the results are based only on in-silico analysis.

Recommendation: Major revision. The study is interesting and technically solid, but several clarifications and wording revisions are needed before it is suitable for publication.

Reviewer #3: The manuscript repeatedly frames the observed behaviors of c_AMP_1 and c_AMP_2 as evidence of distinct “dual antimicrobial mechanisms.” While the molecular dynamics simulations are extensive (300 ns) and technically well executed, this interpretation exceeds what can be robustly inferred from single-peptide, in silico membrane simulations.

Specifically, the two behaviors described—(i) surface-associated, parallel alignment of c_AMP_1 and (ii) deeper, tilted or membrane-inserted orientation of c_AMP_2—represent distinct membrane interaction modes, not demonstrated antimicrobial mechanisms. MD simulations of individual peptides can reveal geometric preferences, stability, and lipid perturbation patterns, but they do not, in isolation, establish functional mechanisms such as carpet-like disruption, pore formation, or bactericidal activity.

At several points in the manuscript (title, abstract, Results, and Discussion), language implies functional antimicrobial mechanisms (e.g., “dual-mechanism AMPs,” “disruptive action,” “therapeutic potential”), which are not experimentally validated and cannot be conclusively supported by MD data alone. This framing risks overstating the biological implications of the simulations and conflating compatibility with known models with demonstration of mechanism.

To strengthen the manuscript and align conclusions with the presented evidence, the authors should:

1. Reframe the study explicitly as a computational prioritization and biophysical characterization of candidate AMPs, rather than as a demonstration of antimicrobial mechanisms.

2 Replace mechanistic terminology (e.g., “dual mechanism,” “pore-forming,” “disruptive action”) with language describing interaction modes, orientation states, or membrane perturbation patterns inferred from simulations.

3. Clearly state the limitations of single-peptide MD simulations and avoid implying bactericidal function or therapeutic efficacy in the absence of experimental validation.

4. Ensure consistency of this revised framing across the title, abstract, Results, Discussion, and Conclusions.

5. Addressing this conceptual issue does not require additional experimental data, but it does require a careful and systematic revision of the manuscript’s interpretative framework.

6. The membrane models used for A. baumannii, K. pneumoniae, and P. aeruginosa are not equivalent. While A. baumannii is modeled using an asymmetric outer membrane containing Lipid A/LPS, K. pneumoniae and P. aeruginosa are represented by symmetric phospholipid bilayers lacking LPS. This distinction is not clearly justified or discussed, yet results are directly compared across systems. Given the known impact of LPS on peptide binding, insertion, and membrane perturbation, the authors should explicitly clarify the rationale for using different membrane architectures and discuss the implications and limitations this imposes on cross-species comparisons.

7. The in silico toxicity and hemolysis predictors suggest a favorable safety profile; the authors could include this in silico profile.

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Jul 22;21(7):e0353985. doi: 10.1371/journal.pone.0353985.r002

Author response to Decision Letter 1


30 Mar 2026

Dear Editor,

We would like to express our sincere gratitude for acknowledging our manuscript and providing us the opportunity to revise it for possible publication in your esteemed journal of PLOS One.

We thank all the peer reviewers for their constructive and insightful suggestions towards our manuscript. Please find our detailed, point-by-point responses (in blue italics) to the reviewers’ comments below. We have carefully addressed each comment, conducted additional analyses where feasible, and amended the revised manuscript accordingly. We hope that our revised manuscript is now suitable for publication in the journal of “PLOS One”.

Point-by-point response reviewers’ comments

Editor

Comment:

1. The manuscript in its current form overstates the experimental implications of what is fundamentally a computational study. In the current form, manuscript overstates the functional activity of the peptides; all claims should be moderated. The title and several statements in the abstract, results, and discussion should be revised to explicitly indicate that this is an in silico investigation and that the reported antimicrobial activities are predicted rather than demonstrated.

Author’s Response

We sincerely thank the Editor for this important observation. We fully agree that the original manuscript language inadvertently implied experimental demonstration of antimicrobial activity. Accordingly, we have revised the title, abstract, results, and discussion to explicitly reflect the computational and predictive nature of this study. The revised title now reads: "In silico identification and biophysical characterization of candidate antimicrobial peptides from the Indian marine microbiome targeting multidrug-resistant ESKAPE pathogens." Throughout the manuscript, terms such as "dual mechanisms of disruptive action" and "functional peptide candidates" have been replaced with "distinct membrane interaction modes" and "candidate peptides," respectively, to ensure all claims are appropriately moderated and consistent with the in silico scope of the work. These changes have been made in the Title (Page 1), Abstract (Page 2), and Conclusion section (Section 5, Page 24) of the revised manuscript.

Comment:

2. The absence of any wet-lab validation is a significant limitation and either wet-lab experiments should be done or more clearly acknowledged, accompanied by a concrete experimental roadmap (e.g., MIC testing, membrane leakage, and cytotoxicity assays).

Author’s Response

We thank the Editor for raising this important point. We acknowledge that the absence of experimental validation is a significant limitation of the present study. As this work is a purely computational investigation, wet-lab experiments were beyond the scope of the current manuscript. However, we have now explicitly acknowledged this limitation and included a concrete experimental roadmap for future validation at the end of the Discussion section (Section 4, Page 22) of the revised manuscript. The proposed roadmap includes: (i) minimum inhibitory concentration (MIC) assays against representative ESKAPE strains, (ii) membrane permeabilization assays using fluorescent dye uptake (e.g., SYTOX Green or propidium iodide), (iii) membrane leakage assays using liposome models, and (iv) hemolysis and cytotoxicity assays on mammalian cell lines to assess selectivity and safety.

Comment:

3. The rationale for selecting only two peptides for molecular dynamics simulations is insufficiently justified and should either be clarified or expanded to include additional candidates.

Author’s Response

We thank the Editor for this important observation. We acknowledge that the rationale for selecting c_AMP_1 and c_AMP_2 for molecular dynamics simulations was not sufficiently articulated in the original manuscript. The manuscript already describes the upstream filtering steps, including a length cut-off of ≤50 amino acids, presence of arginine and tryptophan residues, and pLM4CPPs-based cell-penetrating peptide prediction, that reduced the candidate pool to 10 peptides (Section 3.1, Page 12). From these 10, c_AMP_1 and c_AMP_2 were specifically chosen for all-atom MD simulations based on a multi-criteria evaluation: (i) highest consensus scores across all six machine learning prediction tools, (ii) contrasting yet complementary physicochemical profiles - c_AMP_1 exhibiting a high net positive charge (+11) and strong amphiphilicity (1.59), while c_AMP_2 showed moderate charge (+6) and balanced hydrophobicity (0.89), (iii) structurally distinct AlphaFold3-predicted conformations, c_AMP_1 adopting a continuous α-helical structure and c_AMP_2 a semi-helical conformation with flexible termini, enabling a meaningful comparative biophysical analysis, and (iv) the considerable computational demands of 300 ns all-atom simulations across three bacterial membrane systems, which necessitated a focused selection of the most structurally divergent candidates. This rationale has now been explicitly clarified in Results (Section 3.2, Page 13) and Methods (Section 2.4, Page 8) of the revised manuscript.

Comment:

4. Furthermore, given the reliance on Arg/Trp-based rules for cell-penetrating behavior, the authors should cross-validate their shortlisted peptides using established CPP resources such as CPPsite 2.0, CellPPDmod.

Author’s Response

We thank the Editor for this valuable suggestion. As recommended, we have cross-validated all ten shortlisted peptides using CellPPD-Mod and CPPsite 3.0 (an updated version of CPPsite 2.0), in addition to the originally used pLM4CPPs model. CPP activity was independently predicted using two machine learning-based tools - pLM4CPPs and CellPPD-Mod. Nine out of ten peptides were consistently predicted as CPPs by both tools. One peptide, c_AMP_6, yielded conflicting predictions, classified as CPP by pLM4CPPs but as Non-CPP by CellPPD-Mod, and this discrepancy has been duly acknowledged in the revised manuscript. Additionally, similarity searches against the CPPsite 3.0 database of experimentally validated CPPs using the Smith-Waterman algorithm were conducted as a complementary novelty assessment. All ten candidates yielded low alignment scores (13-19) over short local windows (3-9 residues), indicating no significant full-length similarity to any known CPP in the database. The prediction thresholds applied for each tool have been clearly stated in the Methods section. These results have been incorporated into Methods (Section 2.4, Page 8) and Results (Section 3.1, Page 12) of the revised manuscript and summarized in Supplementary Tables S3 and S4.

Comment:

5. In addition, many experimentally validated antitubercular peptides are absent from general AMP repositories used to train current predictors, which can affect sensitivity for Mycobacterium-active peptides. Therefore, benchmarking against specialized datasets and tools such as AntiTbPdb and AntiTbPred would also help assess the sensitivity of their pipeline, particularly for anti-mycobacterial relevance.

Author’s Response

We thank the Editor for this insightful comment. We acknowledge that general AMP prediction tools may underrepresent experimentally validated antitubercular peptides in their training datasets, potentially limiting the sensitivity of the pipeline for identifying Mycobacterium-active peptides. We wish to clarify that the primary scope of the present study is the identification of candidate AMPs targeting Gram-negative ESKAPE pathogens, specifically Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, and not Mycobacterium tuberculosis. Nevertheless, in response to the Editor's suggestion, we have conducted an exploratory screening of all ten shortlisted candidate peptides using AntiTbPred. All ten candidates were predicted as potential anti-tubercular peptides, with scores ranging from 0.26 to 1.72, suggesting possible broad-spectrum activity that warrants further investigation. We have clearly stated in the revised manuscript that this analysis is purely exploratory in nature and that any anti-mycobacterial activity requires dedicated experimental validation using specialized assays. A note acknowledging the limitation of general AMP predictors for Mycobacterium-specific activity and recommending AntiTbPdb-based benchmarking as a direction for future work has also been added. These additions have been incorporated into the Discussion section (Section 4, Page 23) of the revised manuscript. The AntiTbPred results are summarized in Supplementary Table S5.

Comment:

6. Finally, the translational framing would be strengthened by comparing the lead peptides with characteristics of clinically approved therapeutics using curated resources such as THPdb, SATPdb etc. and by more deeply engaging with recent marine AMP and membrane-modeling literature.

Author’s Response

We thank the Editor for this constructive suggestion. In response to the first part of this comment, similarity searches were performed for c_AMP_1 and c_AMP_2 against THPdb2, a curated database of FDA-approved therapeutic peptides and proteins, using the Smith-Waterman algorithm. No statistically significant matches were identified, c_AMP_1 returned a best hit with an E-value of 1.7 and c_AMP_2 with an E-value of 6.2, confirming that both lead peptides are structurally distinct from currently approved therapeutic peptides. Importantly, both candidates fall within the "Long Peptides (21-50 AA)" category of THPdb2, which encompasses 45 unique FDA-approved therapeutic peptides, indicating that their length profile is consistent with clinically approved peptide therapeutics. Furthermore, their strongly cationic nature, amphipathic architecture, and predicted membrane-targeting properties align well with the physicochemical characteristics associated with approved antimicrobial peptide therapeutics, collectively supporting their translational potential as scaffolds for future peptide-based drug development. These observations have been incorporated into the Discussion section (Section 4, Page 23) of the revised manuscript, and the THPdb2 similarity search results are provided in Supplementary Table S6. In response to the second part of this comment, we have expanded our engagement with recent marine AMP discovery and membrane-modeling literature by incorporating additional relevant citations in the Introduction and Discussion sections of the revised manuscript. All newly added references are highlighted in yellow in the reference section of the revised manuscript for the Editor's and Reviewer's convenience.

Reviewer #1

Comments:

1. Dear Author, the article titled "Uncovering dual-mechanism antimicrobial peptides from the Indian marine microbiome to combat multidrug-resistant ESKAPE Pathogens" was reviewed. This article provides useful information for its readers. Please make the following correction:

Some references are outdated, please use the new references.

Authors' Response

We thank the Reviewer for this comment. We have carefully reviewed all citations in the manuscript and updated or supplemented references where more recent publications are available. References pertaining to specific software tools and prediction algorithms - including MEGAHIT (Li et al., 2016), CHARMM-GUI (Lee et al., 2016), FATSLiM (Buchoux, 2017), CONAN (Mercadante et al., 2018), AMPScanner v2 (Veltri et al., 2018), and APIN (Su et al., 2019) - have been retained as their original publications, as these are the primary citations for the respective tools. For conceptual and mechanistic citations, the following older references have been supplemented with more recent literature: (i) Khandelia & Kaznessis (2007) supplemented with Necula et al. (2023) for cation-π interactions in AMP membrane binding; (ii) Kooijman et al. (2007) supplemented with Graber et al. (2022) for hydrogen bond interactions with phospholipid headgroups; (iii) Mukherjee et al. (2017) supplemented with Ma et al. (2024) for membrane thinning in MD simulations; (iv) Hong et al. (2019) supplemented with Sun et al. (2022) for melittin membrane insertion; and (v) Bobone & Stella (2019) replaced with Ma et al. (2024) for AMP selectivity toward bacterial membranes. All newly added references are highlighted in yellow in the reference section of the revised manuscript for the Editor's and Reviewer's convenience. These updates have been incorporated throughout the revised manuscript.

Reviewer #2

The authors analyze five Indian marine metagenomic datasets to identify antimicrobial peptide candidates using six prediction tools. After applying additional filters based on peptide length, amino acid composition, and predicted cell-penetrating properties, they reduce the set to ten peptides. Two of these are then selected for molecular dynamics simulations with Gram-negative membrane models. The differences in how these peptides interact with the membranes are described in the Results and discussed as possible dual mechanisms. While the overall workflow is logical and clearly presented, several aspects of the methodology and interpretation require clarification and more cautious framing.

Author’s Response

We sincerely thank the Reviewer for this thoughtful summary of our work and for acknowledging the logical and clear presentation of the overall workflow. We appreciate the constructive feedback regarding the areas requiring clarification and more cautious framing. We fully agree with the Reviewer's assessment that several aspects of the methodology and interpretation required additional clarity and moderation, particularly with respect to the characterization of the observed peptide-membrane interaction differences as "dual mechanisms." We have carefully addressed each of the specific concerns raised, as detailed in our point-by-point responses below. The manuscript has been revised accordingly to provide greater methodological transparency and to ensure that all interpretations are appropriately aligned with the in silico scope of the study.

Comment:

1. The Methods section should clearly state (i) the total number of peptides advanced to MD simulations, (ii)Whether c_AMP_1 and c_AMP_2 were the only peptides simulated, and (iii) the criteria used to select them (Charge, hydrophobic moment, predictable activity, or structural diversity).

Author’s Response

We thank the Reviewer for this important observation. We confirm that c_AMP_1 and c_AMP_2 were the only two peptides advanced to all-atom MD simulations in this study. Their selection from the ten shortlisted candidates was based on a multi-criteria evaluation framework considering: (i) net charge - c_AMP_1 exhibiting the highest net positive charge (+11) and c_AMP_2 a moderate charge (+6), representing contrasting electrostatic profiles; (ii) hydrophobic moment and amphiphilicity index - c_AMP_1 with 1.59 and c_AMP_2 with 0.89, reflecting distinct hydrophobic distributions; (iii) predicted membrane activity based on physicochemical profiling via DBAASP; and (iv) structural diversity - c_AMP_1 adopting a continuous α-helical conformation and c_AMP_2 a semi-helical structure with flexible termini as predicted by AlphaFold3. These clarifications have now been explicitly incorporated into Methods (Section 2.4, Page 8) and Results (Section 3.2, Page 13) of the revised manuscript.

Comment:

2. The claim of "dual mechanisms" seems somewhat stronger than what is directly supported by the simulation results. The observed differences mainly show distinct membrane interaction behaviors in the MD simulations, rather than clearly separate antimicrobial mechanisms. The reported analyses describe interaction patterns but do not directly demonstrate effects such as pore formation or membrane permeabilization. The authors may consider softening the wording in the Discussion and Conclusions to better reflect the in silico scope of the results.

Author’s Response

We thank the Reviewer for this important and valid observation. We fully agree that the MD simulation data describe distinct membrane interaction modes and orientation behaviors rather than directly demonstrating functional antimicrobial mechanisms such as pore formation or membrane permeabilization. Accordingly, we have carefully revised the Discussion and Conclusions sections

Attachment

Submitted filename: Response to Reviewers.docx

pone.0353985.s004.docx (36.8KB, docx)

Decision Letter 1

Salman Sadullah Usmani, Salman Sadullah Usmani

14 Apr 2026

-->PONE-D-25-55465R1-->-->In silico identification and biophysical characterization of candidate antimicrobial peptides from the Indian marine microbiome targeting multidrug-resistant ESKAPE pathogens-->-->PLOS One

Dear Dr. Dehury,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 29 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Salman Sadullah Usmani, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #2: Partly

Reviewer #3: Yes

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #2: N/A

Reviewer #3: N/A

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #2: The authors have satisfactorily addressed the concerns raised in the previous round of review. The manuscript has improved in terms of clarity, methodological description, and overall framing.

In particular, the interpretation of the molecular dynamics results has been revised appropriately, and the conclusions are now better aligned with the in-silico nature of the study. The rationale for peptide selection and the description of the simulation setup is now clearer. The manuscript also includes a more explicit discussion of its limitations, including the absence of experimental validation and independent benchmarking.

One minor point remains regarding consistency of wording. In a few sections, particularly the conclusion, the language still slightly overemphasizes potential therapeutic implications. This should be moderated to ensure it remains fully consistent with the computational scope of the study.

Overall, the manuscript is now scientifically sound and suitable for publication after minor revision.

Reviewer #3: (No Response)

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

PLoS One. 2026 Jul 22;21(7):e0353985. doi: 10.1371/journal.pone.0353985.r004

Author response to Decision Letter 2


16 Apr 2026

Dear Editor,

We would like to express our sincere gratitude for acknowledging our manuscript and providing us the opportunity to revise it for possible publication in your esteemed journal of PLOS One.

We thank all the peer reviewers for their constructive and insightful suggestions towards our manuscript. Please find our detailed, point-by-point responses (in blue italics) to the reviewers’ comments below. We have carefully addressed each comment, conducted additional analyses where feasible, and amended the revised manuscript accordingly. We hope that our revised manuscript is now suitable for publication in the journal of “PLOS One”.

Point-by-point response reviewers’ comments

Reviewer #2

The authors have satisfactorily addressed the concerns raised in the previous round of review. The manuscript has improved in terms of clarity, methodological description, and overall framing. In particular, the interpretation of the molecular dynamics results has been revised appropriately, and the conclusions are now better aligned with the in-silico nature of the study. The rationale for peptide selection and the description of the simulation setup is now clearer. The manuscript also includes a more explicit discussion of its limitations, including the absence of experimental validation and independent benchmarking.

Author’s Response

We sincerely thank the Reviewer for this positive and encouraging assessment of the revised manuscript. We are glad that the revisions addressing the interpretation of molecular dynamics results, the clarity of the peptide selection rationale, the simulation setup description, and the explicit discussion of limitations have met the Reviewer's expectations. We have further addressed the single remaining minor point identified below.

Comment:

1. One minor point remains regarding consistency of wording. In a few sections, particularly the conclusion, the language still slightly overemphasizes potential therapeutic implications. This should be moderated to ensure it remains fully consistent with the computational scope of the study.

Author’s Response

We thank the Reviewer for this observation. We agree that the language in a few sections inadvertently overemphasized the therapeutic implications of the study beyond what is directly supported by the in silico evidence. Accordingly, we have carefully reviewed the manuscript and made targeted revisions in the Abstract (Page 2), Introduction (Section 1, Page 6), Discussion (Section 4, Page 23) and Conclusion (Section 5, Page 24) to moderate such language. Phrases implying confirmed findings or direct therapeutic applicability have been replaced with appropriately qualified expressions that accurately reflect the computational and predictive scope of the study. We believe these revisions ensure that the manuscript is now fully consistent in its framing throughout.

Reviewer #3

No comments were provided.

Author’s Response

We thank the reviewer for recommending our work for publication.

Attachment

Submitted filename: Response_to_Reviewers_auresp_2.docx

pone.0353985.s005.docx (15.1KB, docx)

Decision Letter 2

Salman Sadullah Usmani, Salman Sadullah Usmani, Salman Sadullah Usmani

15 Jun 2026

-->PONE-D-25-55465R2-->-->In silico identification and biophysical characterization of candidate antimicrobial peptides from the Indian marine microbiome targeting multidrug-resistant ESKAPE pathogens-->-->PLOS One

Dear Dr. Dehury,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 30 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Salman Sadullah Usmani, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #2: All comments have been addressed

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #2: Partly

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #2: N/A

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #2: No

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #2: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #2: The revised manuscript is improved compared to the previous version, and the authors have addressed many of the earlier concerns. The topic is important, and the overall workflow of the

study is presented clearly.

Some parts of the manuscript still sound stronger than what is shown in the study. The MD simulations show different ways the peptides interact with the membranes, but they do not directly

prove antimicrobial mechanisms or therapeutic effects.

The wording in the Abstract, Results, Discussion and Conclusion should be made more careful and consistent with the computational nature of the work.

There are still a few inconsistencies regarding the peptides used for the MD simulations. In some sections, three peptides are mentioned, while the detailed analysis is only presented for c_AMP_1

and c_AMP_2. This should be corrected throughout the manuscript.

In some places, the interpretation of the membrane interaction results goes beyond what can be directly concluded from the simulations. Since no experimental validation has been included, these points should be discussed more cautiously.

Overall, the manuscript has improved after revision, but some additional corrections are still needed to improve clarity and maintain consistency throughout the study

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

PLoS One. 2026 Jul 22;21(7):e0353985. doi: 10.1371/journal.pone.0353985.r006

Author response to Decision Letter 3


22 Jun 2026

Dear Editor,

We would like to express our sincere gratitude for acknowledging our manuscript and providing us the opportunity to revise it for possible publication in your esteemed journal of PLOS One.

We thank all the peer reviewers for their constructive and insightful suggestions towards our manuscript. Please find our detailed, point-by-point responses (in blue italics) to the reviewer’s comments below. We have carefully addressed each comment and amended the revised manuscript accordingly, with all changes marked using track changes. We hope that our revised manuscript is now suitable for publication in the journal of “PLOS One”.

Point-by-point response reviewers’ comments

Reviewer #2

The revised manuscript is improved compared to the previous version, and the authors have addressed many of the earlier concerns. The topic is important, and the overall workflow of the

study is presented clearly.

Author’s Response

We sincerely thank the Reviewer for the careful re-evaluation of our manuscript and for acknowledging the improvements made in the revised version. We are grateful for the recognition that the topic is important and that the overall workflow is presented clearly. We have taken the remaining comments seriously and have made targeted revisions throughout the Abstract, Results, Discussion, and Conclusion to ensure that the language is fully consistent with the computational and predictive nature of the study, that the membrane-interaction results are interpreted cautiously in the absence of experimental validation, and that the number of peptides used for the molecular dynamics simulations is stated unambiguously. Our point-by-point responses are provided below, and all corresponding changes have been marked using track changes in the revised manuscript.

Comment:

1. Some parts of the manuscript still sound stronger than what is shown in the study. The MD simulations show different ways the peptides interact with the membranes, but they do not directly prove antimicrobial mechanisms or therapeutic effects.

Author’s Response

We thank the Reviewer for this important observation. We fully agree that the molecular dynamics simulations characterize predicted peptide-membrane interaction modes and do not, in themselves, demonstrate antimicrobial mechanisms or therapeutic effects. Accordingly, we have revised the concluding statements of the Abstract (Page 2), the Discussion (Section 4, Page 23), and the Conclusion (Section 5, Page 24) to remove wording that could imply proven activity or therapeutic readiness. Expressions such as “effectively prioritizes,” “conducive to therapeutic development,” and “strongly support” have been replaced with appropriately qualified phrasing that frames the peptides as computational candidates requiring experimental validation. We note that the manuscript already contains a dedicated paragraph in the Discussion explicitly stating that single-peptide MD simulations cannot establish pore formation, permeabilization, or bactericidal activity; the present revisions bring the surrounding summary statements into line with that caveat.

Comment:

2. The wording in the Abstract, Results, Discussion and Conclusion should be made more careful and consistent with the computational nature of the work.

Author’s Response

We thank the Reviewer for this suggestion and have carried out a careful pass across the Abstract, Results, Discussion, and Conclusion to harmonize the language with the computational scope of the work. Subjective or comparative terms that implied functional superiority, such as “underperformed” and “superior membrane adaptability” in Results (Section 3.5, Page 17), have been rephrased in neutral, observation-based terms tied explicitly to the simulated systems. Verbs describing simulation outcomes such as “revealed,” “exhibited” have, where appropriate, been softened to “indicated” or “displayed,” and qualifiers such as “in the simulations” / “in silico” have been retained or added so that descriptive and interpretive statements read consistently throughout. Together with the changes made under the preceding and following comments, these edits ensure a uniform, computationally qualified tone across all four sections.

Comment:

3. There are still a few inconsistencies regarding the peptides used for the MD simulations. In some sections, three peptides are mentioned, while the detailed analysis is only presented for c_AMP_1 and c_AMP_2. This should be corrected throughout the manuscript.

Author’s Response

We thank the Reviewer for highlighting this point and apologize for the lack of clarity. We confirm that exactly two peptides, c_AMP_1 and c_AMP_2, were advanced to molecular dynamics simulations; all detailed analyses correspond to these two peptides. The recurring reference to “three” in the manuscript denotes the three bacterial membrane systems (A. baumannii, K. pneumoniae, and P. aeruginosa), not three peptides, and the close juxtaposition of “two peptides” and “three membranes” may have caused this ambiguity. To remove any possible confusion, we have revised the simulation-design statement in Materials and methods (Section 2.5, Page 9) to state the design explicitly as “two peptides × three membranes = six independent MD systems,” and we have re-checked the Abstract, Methods (Sections 2.4-2.5), Results (Sections 3.3-3.6), and Discussion (Section 4) to ensure that the two-peptide selection and the three-membrane design are stated consistently and cannot be conflated. The peptide count is now unambiguous throughout.

Comment:

4. In some places, the interpretation of the membrane interaction results goes beyond what can be directly concluded from the simulations. Since no experimental validation has been included, these points should be discussed more cautiously.

Author’s Response

We agree with the Reviewer that, in the absence of experimental validation, certain interpretations were stated more definitively than the simulations permit. We have therefore revised these statements to distinguish what is directly observed in the trajectories from what would require experimental confirmation. In Results (Section 3.5, Page 17), the causal phrasing “indicating that c_AMP_2 inserts more deeply… and induces localized lipid compression” has been changed to the observation-level “consistent with deeper insertion… within the simulated bilayers.” In the Discussion (Section 4, Page 21), the inference that a deeper orientation “could enhance permeabilization” has been qualified to state explicitly that permeabilization cannot be inferred from structural simulations alone and requires dedicated experimental assays. These revisions complement the existing limitations paragraph in the Discussion, which already notes that single-peptide simulations cannot establish pore formation or bactericidal activity, and ensure that all mechanistic interpretations are now framed as predicted, simulation-derived observations.

Attachment

Submitted filename: Response_to_Reviewers_auresp_3.docx

pone.0353985.s006.docx (17.8KB, docx)

Decision Letter 3

Salman Sadullah Usmani, Salman Sadullah Usmani, Salman Sadullah Usmani, Salman Sadullah Usmani

2 Jul 2026

In silico identification and biophysical characterization of candidate antimicrobial peptides from the Indian marine microbiome targeting multidrug-resistant ESKAPE pathogens

PONE-D-25-55465R3

Dear Dr. Dehury,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Salman Sadullah Usmani, Ph.D.

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #2: All comments have been addressed

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #2: Yes

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #2: N/A

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #2: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #2: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #2: The revised manuscript is improved, and the authors have addressed my previous comments satisfactorily. The interpretation is now more appropriately cautious and consistent with the computational nature of the study. I have o further concerns.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.-->

Reviewer #2: No

**********

Acceptance letter

Salman Sadullah Usmani, Salman Sadullah Usmani, Salman Sadullah Usmani, Salman Sadullah Usmani

PONE-D-25-55465R3

PLOS One

Dear Dr. Dehury,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Salman Sadullah Usmani

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Supporting tables and figures referenced in the main text.

    (DOCX)

    pone.0353985.s001.docx (1.7MB, docx)
    S2 File. List of high-confidence antimicrobial peptides (c_AMPs) predicted from Indian marine metagenomic datasets.

    (ZIP)

    pone.0353985.s002.zip (2.3MB, zip)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0353985.s004.docx (36.8KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_2.docx

    pone.0353985.s005.docx (15.1KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_3.docx

    pone.0353985.s006.docx (17.8KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES